var title_f18_30_18912="Barium enema traumatic diaphragmatic hernia of colon";
var content_f18_30_18912=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Barium enema traumatic diaphragmatic hernia of colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 509px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The single contrast barium enema shows the hepatic flexure herniated&nbsp;through the dome of the left hemidiaphragm (arrowhead). The hiatus lies between the two white arrows. The position of the hernia suggests a traumatic etiology.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_30_18912=[""].join("\n");
var outline_f18_30_18912=null;
var title_f18_30_18913="Sunburn";
var content_f18_30_18913=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Sunburn (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/30/18913/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/30/18913/contributors\" id=\"au7188\">",
"       Sylvia Brice, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/30/18913/contributors\" id=\"au7184\">",
"       Kathryn R Shrift, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/30/18913/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/30/18913/contributors\" id=\"se7157\">",
"       Robert P Dellavalle, MD, PhD, MSPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/30/18913/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/30/18913/contributors\" id=\"de7805\">",
"       Rosamaria Corona, MD, DSc",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?18/30/18913?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      SUNBURN OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Sunburn occurs when skin is burned by ultraviolet (UV) radiation, most often after being in the sun for too long. It is common, with more than 30 percent of adults and 70 percent of children and adolescents reporting at least one sunburn during the course of a year. Although most sunburns are not severe, a lifetime of sun exposure",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     frequent sunburns significantly increases your risk of developing skin cancer, wrinkles, and other cosmetic concerns.",
"    </p>",
"    <p>",
"     This article addresses the symptoms, causes, potential complications, and treatment of sunburn. Prevention of sunburn is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/60/33729?source=see_link\">",
"      \"Patient information: Sunburn prevention (Beyond the Basics)\"",
"     </a>",
"     .) Severe sunburns are treated like other skin burns, and are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/55/32625?source=see_link\">",
"      \"Patient information: Skin burns (Beyond the Basics)\"",
"     </a>",
"     .) More detailed information about sunburn is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30136?source=see_link\">",
"      \"Sunburn\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      SUNBURN SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Unlike other types of skin burns, sunburn is not immediately apparent because redness develops between three and five hours after being out in the sun. Common symptoms of sunburn include reddened skin that is hot to the touch and skin pain; more severe sunburns cause skin swelling and blistering (",
"     <a class=\"graphic graphic_picture graphicRef71537 \" href=\"UTD.htm?22/18/22816\">",
"      picture 1",
"     </a>",
"     and",
"     <a class=\"graphic graphic_picture graphicRef52757 \" href=\"UTD.htm?17/8/17539\">",
"      picture 2",
"     </a>",
"     ). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/55/32625?source=see_link\">",
"      \"Patient information: Skin burns (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Redness peaks approximately 12 to 24 hours after sun exposure and fades over 72 hours.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      SUNBURN CAUSES AND RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     Normally, the skin is protected from the sun by a substance in the skin called melanin. Melanin is a pigment (coloring) that causes your skin to appear light or dark colored. If your skin is exposed to excessive UV radiation from the sun or a tanning bed, it becomes burned.",
"    </p>",
"    <p>",
"     The amount of UV radiation required to burn your skin depends upon:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The amount of melanin in your skin. In general, people with fair skin and light-colored hair have less melanin and are at higher risk of sunburn compared with people with darker-colored skin. Some people can develop sunburn after less than 15 minutes of sun exposure.",
"      </li>",
"      <li>",
"       Where you are. People in regions that are closest to the equator and high altitudes (eg, mountainous areas) are at higher risk for developing sunburn.",
"      </li>",
"      <li>",
"       Certain medications make the skin more sensitive to burning. This includes nonsteroidal antiinflammatory drugs (eg, ibuprofen), quinolone and tetracycline antibiotics (eg, Cipro&reg;, tetracycline), furosemide (Lasix&reg;) and hydrochlorothiazide (HCTZ), psoralens",
"       <span class=\"nowrap\">",
"        (methoxsalen/Oxsoralen&reg;)",
"       </span>",
"       and phenothiazines (eg, compazine). If you take one or more of these medications, you should avoid the sun and use protective measures (eg, sunscreen) to avoid sunburn.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      SUNBURN COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Sunburn is associated with premature aging and wrinkling of the skin as well as skin cancer, including malignant melanoma, a serious form of skin cancer. Sun exposure and ultraviolet damage can also increase the risk of developing cataracts (when the lens in the eye becomes cloudy). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/6/28772?source=see_link\">",
"      \"Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      SUNBURN TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatments for sunburn can help to relieve skin discomfort. You should stay out of the sun until your skin redness and pain resolve. You can take a non-steroidal antiinflammatory drugs (NSAIDs) such as aspirin, ibuprofen, or naproxen to relieve pain. These medications are especially helpful if you take them as soon as you notice pain; the benefit of NSAIDs decreases after 24 hours.",
"    </p>",
"    <p>",
"     For mild sunburns, there are a number of products advertised to relieve pain, including cool compresses, aloe-based lotions, and lotions or sprays with a local anesthetic (numbing medication, eg, Solarcaine&reg;, Dermaplast&reg;). Although studies have not proven that these products are helpful, they are not likely to be harmful. However, these products do not reduce the long-term risks of sunburn (eg, skin cancer).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      PREVENTING SUNBURN",
"     </span>",
"    </p>",
"    <p>",
"     The prevention of sunburn is discussed in a separate article. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/60/33729?source=see_link\">",
"      \"Patient information: Sunburn prevention (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      WHEN TO SEEK HELP",
"     </span>",
"    </p>",
"    <p>",
"     If you have a severe sunburn, call your healthcare provider to determine if you can use treatment at home, or if you need to be evaluated in the office or an emergency department.",
"    </p>",
"    <p>",
"     Symptoms of a severe sunburn include severe skin pain and skin blistering (",
"     <a class=\"graphic graphic_picture graphicRef52757 \" href=\"UTD.htm?17/8/17539\">",
"      picture 2",
"     </a>",
"     ). People with severe sunburn can also have heat stroke or heat exhaustion, which can cause fever, headache, confusion, nausea, vomiting, blurry vision, and fainting. If you have any of these problems, you should go to the emergency department immediately.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our Web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32164306\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32164314\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/20/23874?source=see_link\">",
"      Patient information: Sunburn (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/46/42722?source=see_link\">",
"      Patient information: Melanoma skin cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/26/26018?source=see_link\">",
"      Patient information: Skin cancer (non-melanoma) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/8/19586?source=see_link\">",
"      Patient information: Actinic keratosis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32164391\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"     <br/>",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/6/28772?source=see_link\">",
"      Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/60/33729?source=see_link\">",
"      Patient information: Sunburn prevention (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/55/32625?source=see_link\">",
"      Patient information: Skin burns (Beyond the Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32164406\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"     <br/>",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=see_link\">",
"      Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18200?source=see_link\">",
"      Epidemiology, natural history, and diagnosis of actinic keratosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=see_link\">",
"      Epidemiology and clinical features of basal cell carcinoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18073?source=see_link\">",
"      Primary prevention of melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/16/16650?source=see_link\">",
"      Screening and early detection of melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30136?source=see_link\">",
"      Sunburn",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13690?source=see_link\">",
"      Treatment and prognosis of basal cell carcinoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=see_link\">",
"      Treatment and prognosis of cutaneous squamous cell carcinoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30968?source=see_link\">",
"      Treatment of actinic keratosis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/sunexposure.html\">",
"      www.nlm.nih.gov/medlineplus/sunexposure.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Center for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.cdc.gov/cancer/skin/chooseyourcover/\">",
"      www.cdc.gov/cancer/skin/chooseyourcover/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.nci.nih.gov/cancertopics/pdq/prevention/skin/Patient/page2\">",
"      www.nci.nih.gov/cancertopics/pdq/prevention/skin/Patient/page2",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Environmental Protection Agency",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.epa.gov/sunwise/\">",
"      www.epa.gov/sunwise/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Skin Cancer Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.skincancer.org/index.php\">",
"      www.skincancer.org/index.php",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Council on Skin Cancer Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.skincancerprevention.org\">",
"      www.skincancerprevention.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?18/30/18913/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 8, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?18/30/18913?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18913/abstract/1\">",
"      Moloney FJ, Collins S, Murphy GM. Sunscreens: safety, efficacy and appropriate use. Am J Clin Dermatol 2002; 3:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18913/abstract/2\">",
"      Diffey BL. When should sunscreen be reapplied? J Am Acad Dermatol 2001; 45:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18913/abstract/3\">",
"      Saraiya M, Hall HI, Uhler RJ. Sunburn prevalence among adults in the United States, 1999. Am J Prev Med 2002; 23:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18913/abstract/4\">",
"      Geller AC, Colditz G, Oliveria S, et al. Use of sunscreen, sunburning rates, and tanning bed use among more than 10 000 US children and adolescents. Pediatrics 2002; 109:1009.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f18_30_18913=[""].join("\n");
var outline_f18_30_18913=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           SUNBURN OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           SUNBURN SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           SUNBURN CAUSES AND RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           SUNBURN COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           SUNBURN TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           PREVENTING SUNBURN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           WHEN TO SEEK HELP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/18/22816\" title=\"picture 1\">",
"           Sunburn back PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/8/17539\" title=\"picture 2\">",
"           Sunburn blistering PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f18_30_18914="Patient information: Epididymitis (The Basics)";
var content_f18_30_18914=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17184\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/43/22194\">",
"         Male reproductive anatomy",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/52/23362\">",
"         Patient information: Chlamydia and gonorrhea (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/57/1940\">",
"         Patient information: Screening for sexually transmitted diseases (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/21/1363\">",
"         Patient information: Teen sexuality (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/8/35973\">",
"         Patient information: Adolescent sexuality (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/14/24802\">",
"         Patient information: Chlamydia (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/44/1730\">",
"         Patient information: Gonorrhea (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Epididymitis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/epididymitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H21144080\">",
"      <span class=\"h1\">",
"       What is epididymitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Epididymitis is the term doctors use when the epididymis gets inflamed. The epididymis is a small organ that sits on top of the testicle (",
"      <a class=\"graphic graphic_figure graphicRef68075 \" href=\"UTD.htm?21/43/22194\">",
"       figure 1",
"      </a>",
"      ). The testicles are the 2 ball-shaped organs that hang between a man&rsquo;s legs. The epididymis stores sperm and moves it along the male reproductive tract.",
"     </p>",
"     <p>",
"      Different infections and conditions can cause epididymitis. In teens and men who are having sex, epididymitis is commonly caused by chlamydia or gonorrhea. These are 2 different infections that people can catch during sex.",
"     </p>",
"     <p>",
"      Epididymitis can also be caused by other conditions or infections that people don&rsquo;t catch during sex. These things are more likely to cause epididymitis in older men.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21144095\">",
"      <span class=\"h1\">",
"       What are the symptoms of epididymitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Epididymitis causes pain in the testicles or scrotum. The scrotum is the skin sac around the testicles.",
"     </p>",
"     <p>",
"      Besides pain, epididymitis can also cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Swelling of the scrotum or testicles",
"       </li>",
"       <li>",
"        Redness of the scrotum",
"       </li>",
"       <li>",
"        A fever",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21144110\">",
"      <span class=\"h1\">",
"       Should I see my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. See your doctor or nurse if you have pain or swelling in your testicles or scrotum.",
"     </p>",
"     <p>",
"      If your pain is severe, and your doctor or nurse can&rsquo;t see you right away, you should go to the emergency room.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21144125\">",
"      <span class=\"h1\">",
"       Is there a test for epididymitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will ask about your symptoms and do an exam. He or she will also probably do:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Urine tests",
"       </li>",
"       <li>",
"        An ultrasound of your scrotum &ndash; An ultrasound is an imaging test that uses sound waves to create pictures of the inside of the body.",
"       </li>",
"       <li>",
"        Lab tests &ndash; If you have discharge from your urethra (the opening in your penis where urine leaves your body), your doctor or nurse will take a sample of the discharge. He or she will send the sample to a lab for tests.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21144140\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To help with the pain and swelling, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Put a cold gel pack, bag of ice, or bag of frozen vegetables on the area every few hours, for 15 minutes each time.",
"       </li>",
"       <li>",
"        Wear a jock strap to support your scrotum.",
"       </li>",
"       <li>",
"        Take an over-the-counter medicine to treat your pain. Over-the-counter medicines include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sample brand name: Tylenol&reg;),",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;), and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21144155\">",
"      <span class=\"h1\">",
"       What other treatment might I need?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Other treatment depends on what&rsquo;s causing your epididymitis.",
"     </p>",
"     <p>",
"      If a bacterial infection is causing your epididymitis, your doctor will prescribe antibiotic medicines. Most men can take antibiotic pills at home, but men with a severe infection might need treatment in the hospital.",
"     </p>",
"     <p>",
"      If you are treated for chlamydia or gonorrhea, you should tell all the people you have had sex with recently. They might also be infected (even if they have no symptoms) and need treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21144170\">",
"      <span class=\"h1\">",
"       Can epididymitis be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can help prevent epididymitis that is caused by chlamydia or gonorrhea by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Using a latex condom every time you have sex",
"       </li>",
"       <li>",
"        Avoiding sex when you or your partner has genital itching, discharge, or other symptoms that could be caused by an infection",
"       </li>",
"       <li>",
"        Not having sex",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21144185\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=see_link\">",
"       Patient information: Chlamydia and gonorrhea (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1940?source=see_link\">",
"       Patient information: Screening for sexually transmitted diseases (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/21/1363?source=see_link\">",
"       Patient information: Teen sexuality (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=see_link\">",
"       Patient information: Gonorrhea (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/14/24802?source=see_link\">",
"       Patient information: Chlamydia (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/8/35973?source=see_link\">",
"       Patient information: Adolescent sexuality (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?18/30/18914?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17184 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-201.211.0.116-2CA427E3D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_30_18914=[""].join("\n");
var outline_f18_30_18914=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21144080\">",
"      What is epididymitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21144095\">",
"      What are the symptoms of epididymitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21144110\">",
"      Should I see my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21144125\">",
"      Is there a test for epididymitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21144140\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21144155\">",
"      What other treatment might I need?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21144170\">",
"      Can epididymitis be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21144185\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17184\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/43/22194\">",
"      Male reproductive anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/8/35973?source=related_link\">",
"      Patient information: Adolescent sexuality (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/14/24802?source=related_link\">",
"      Patient information: Chlamydia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=related_link\">",
"      Patient information: Chlamydia and gonorrhea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=related_link\">",
"      Patient information: Gonorrhea (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1940?source=related_link\">",
"      Patient information: Screening for sexually transmitted diseases (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/21/1363?source=related_link\">",
"      Patient information: Teen sexuality (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_30_18915="Oxytocin: Patient drug information";
var content_f18_30_18915=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Oxytocin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     see \"Oxytocin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F205493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pitocin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F205494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Oxytocin for injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10015976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700806",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug to start the labor unless needed. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691643",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to start labor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat bleeding that happens after a birth or an abortion.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691365",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to end your pregnancy.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702665",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to oxytocin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698648",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding a lot (soaking 1 pad per hour).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10918 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-B6AD6E7C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_30_18915=[""].join("\n");
var outline_f18_30_18915=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205493\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205494\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015976\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015978\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015977\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015981\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015982\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015984\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015980\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015986\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=related_link\">",
"      Oxytocin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_30_18916="Excoriation";
var content_f18_30_18916=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Excoriations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Linear excoriations (secondary to scratching) are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_30_18916=[""].join("\n");
var outline_f18_30_18916=null;
var title_f18_30_18917="Gingival enlargement";
var content_f18_30_18917=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 595px\">",
"   <div class=\"ttl\">",
"    Drug-influenced gingival enlargement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 575px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cyclosporine-induced in a young adult who received a kidney transplant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_30_18917=[""].join("\n");
var outline_f18_30_18917=null;
var title_f18_30_18918="Pyoderma gangrenosum large ulcer";
var content_f18_30_18918=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pyoderma gangrenosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A large ulcer with undermined borders and a purulent base is present on the lower extremity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_30_18918=[""].join("\n");
var outline_f18_30_18918=null;
var title_f18_30_18919="Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Drug information";
var content_f18_30_18919=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/3/26676?source=see_link\">",
"    see \"Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/27/8630?source=see_link\">",
"    see \"Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bebulin&reg; VH;",
"     </li>",
"     <li>",
"      Profilnine&reg; SD",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F169690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antihemophilic Agent;",
"     </li>",
"     <li>",
"      Blood Product Derivative;",
"     </li>",
"     <li>",
"      Prothrombin Complex Concentrate (PCC)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F169681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage is expressed in units of factor IX activity and must be individualized based on severity of factor IX deficiency, extent and location of bleeding, and clinical status of patient. When multiple doses are required, administer at 24-hour intervals unless otherwise specified. Administer I.V. only:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Formula for units required to raise blood level %:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bebulin&reg; VH: In general, factor IX 1 unit/kg will increase the plasma factor IX level by 0.8%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Number of Factor IX units required = body weight (kg) x desired factor IX increase (as %) x 1.2 units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Profilnine&reg; SD: In general, factor IX 1 unit/kg will increase the plasma factor IX level by 1%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Number of factor IX units required = bodyweight (kg) x desired factor IX increase (as %) x 1 unit/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     For example, to increase factor IX level to 25% of normal in a 70 kg patient: Number of factor IX units needed = 70 kg x 25 x 1 unit/kg = 1750 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      As a general rule, the level of factor IX required for treatment of different conditions is listed below:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hemorrhage:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Minor bleeding (early hemarthrosis, minor epistaxis, gingival bleeding, mild hematuria):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Bebulin&reg; VH: Raise factor IX level to 20% of normal [typical initial dose: 25-35 units/kg]; generally a single dose is sufficient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Profilnine&reg; SD: Mild-to-moderate bleeding: Raise factor IX level to 20% to 30% of normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Moderate bleeding (severe joint bleeding, early hematoma, major open bleeding, minor trauma, minor hemoptysis, hematemesis, melena, major hematuria):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bebulin&reg; VH: Raise factor IX level to 40% of normal [typical initial dose: 40-55 units/kg]; average duration of treatment is 2 days or until adequate wound healing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Profilnine&reg; SD: Mild-to-moderate bleeding: raise factor IX level to 20% to 30% of normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Major bleeding (severe hematoma, major trauma, severe hemoptysis, hematemesis, melena):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bebulin&reg; VH: Raise factor IX level to &ge;60% of normal [typical initial dose: 60-70 units/kg]; average duration of treatment is 2-3 days or until adequate wound healing. Do not raise &gt;60% in patients who may be predisposed to thrombosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Profilnine&reg; SD: Raise factor IX level to 30% to 50% of normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Surgical procedures:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dental surgery:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bebulin&reg; VH: Raise factor IX level to 40% to 60% of normal on day of surgery [typical dose: 50-60 units/kg]. One infusion, administered 1 hour prior to surgery, is generally sufficient for the extraction of one tooth; for the extraction of multiple teeth, replacement therapy may be required for up to 1 week (See dosing guidelines for",
"     <i>",
"      Minor Surgery",
"     </i>",
"     ).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Profilnine&reg; SD: Raise factor IX level to 50% of normal immediately prior to procedure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Minor surgery:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bebulin&reg; VH: Raise factor IX level to 40% to 60% of normal on day of surgery [typical initial dose: 50-60 units/kg]. Decrease factor IX level from 40% of normal to 20% of normal during initial postoperative period (1-2 weeks or until adequate wound healing) [typical dose: 55 units/kg decreasing to 25 units/kg]. The preoperative dose should be given 1 hour prior to surgery. The average dosing interval may be every 12 hours initially, then every 24 hours later in the postoperative period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Profilnine&reg; SD: Raise factor IX level to 30% to 50% of normal for at least 1 week following surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Major surgery:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bebulin&reg; VH: Raise factor IX level to &ge;60% of normal on day of surgery [typical initial dose: 70-95 units/kg]; do not raise &gt;60% in patients who may be predisposed to thrombosis. Decrease factor IX level from 60% of normal to 20% of normal during initial postoperative period (1-2 weeks) [typical dose: 70 units/kg decreasing to 35 units/kg]; further decrease to maintain a factor IX level of 20% of normal during late postoperative period (&ge;3 weeks) and continuing until adequate wound healing is achieved [typical dose: 35 units/kg decreasing to 25 units/kg]. The preoperative dose should be given 1 hour prior to surgery. The average dosing interval may be every 12 hours initially, then every 24 hours later in the postoperative period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Profilnine&reg; SD: Raise Factor IX level to 30% to 50% of normal for at least 1 week following surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hemorrhage:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Long-term prophylactic treatment:",
"     </i>",
"     Bebulin&reg; VH: 20-30 units/kg once or twice a week may reduce frequency of spontaneous hemorrhage; dosing regimen should be individualized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Warfarin associated hemorrhage (unlabeled use):",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Products contain low or nontherapeutic levels of factor VII component;  therefore, additional fresh frozen plasma (FFP) or factor VIIa may be considered (Masotti, 2011). When immediate INR reversal is required, concomitant use of 1-2 units of  FFP should be considered to ensure acute INR reversal (Baker, 2004; Chong, 2010; Holland, 2009). Administer vitamin K (phytonadione) 5-10 mg by slow I.V. infusion (Guyatt, 2012); vitamin K may be repeated every 12 hours if INR is persistently elevated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Adjusted-dose regimen, weight based (Chong, 2010):",
"     </i>",
"     Profilnine&reg; SD:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     INR &lt;5: 30 units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     INR &gt;5 (emergent): 50 units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If after administration, INR remains &gt;1.2 consider repeating dose and administering more FFP until INR &lt;1.2",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     The following 2 methods have also been suggested, but are not product specific:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Adjusted-dose regimen, weight based (Liumbruno, 2009):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     INR &lt;2.0: 20 units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     INR 2.0-4.0: 30 units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     INR &gt;4.0: 50 units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If after administration, INR remains &gt;1.5 consider repeating dose appropriate for INR.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      May also determine dose based on presenting INR and estimated functional prothrombin complex (PC) expressed as percentage of normal plasma levels (see table; Masotti, 2011):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Units needed to be infused = (",
"     <b>",
"      target",
"     </b>",
"     % of functional PC to be reached &ndash;",
"     <b>",
"      current",
"     </b>",
"     estimated % of functional PC) x kg of body weight",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     <b>",
"      Example:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Patient (weight: 70 kg) presents with INR of 4.5 which corresponds to an",
"     <b>",
"      estimated % functional PC",
"     </b>",
"     of 10% (see table). Target INR of 1.4 corresponds to an",
"     <b>",
"      estimated target % functional PC",
"     </b>",
"     of 40%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Units needed to be infused = (40 - 10) x 70 kg = 2100 units",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Conversion of the INR to Estimated Functional Prothrombin Complex (PC)",
"     </caption>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <thead valign=\"bottom\">",
"      <tr>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         INR Value",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Estimated",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Functional PC",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;5.0",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         5%",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         4-4.9",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         10%",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2.6-3.2",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         15%",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2.2-2.5",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         20%",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1.9-2.1",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25%",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1.7-1.8",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         30%",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1.4-1.6",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         40%",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1.0-1.3",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         100%",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F169686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/27/8630?source=see_link\">",
"      see \"Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F169682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15881408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15881409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F169668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bebulin&reg; VH: Exact potency labeled on each vial [vapor heated; contains heparin and natural rubber/natural latex in packaging]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Profilnine&reg; SD: ~500 units, ~1000 units, ~1500 units [exact potency labeled on each vial; solvent/detergent treated]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F169654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F169671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. administration only; should be infused",
"     <b>",
"      slowly",
"     </b>",
"     . Rate should not exceed 2 mL/minute for Bebulin&reg; VH or 10 mL/minute for Profilnine&reg; SD. Slowing the rate of infusion, changing the lot of medication, or administering antihistamines may relieve some adverse reactions",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F169670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Prevention and control of bleeding in patients with factor IX deficiency (hemophilia B or Christmas disease)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5662083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Emergent correction of warfarin-induced coagulopathy (with clinically significant bleeding);",
"     <b>",
"      Note:",
"     </b>",
"     Products contain low or nontherapeutic levels of factor VII component; use of fresh frozen plasma (FFP) should be considered",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14634078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Factor IX Complex may be confused with Factor IX",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F169688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing, thrombosis (sometimes fatal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, fever, headache, lethargy, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: DIC",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic shock, clotting factor antibodies (development of), heparin-induced thrombocytopenia (with products containing heparin)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F169674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F169658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antibody formation: The development of factor IX antibodies (or inhibitors) has been reported with factor IX therapy (usually occurs within the first 10-20 exposure days); the risk of severe hypersensitivity reactions occurring may be greater in these patients. When clinical response is suboptimal or patient is to undergo surgical procedure, screen for inhibitors. Patients with severe gene defects (eg, gene deletion or inversion) are more likely to develop inhibitors (WFH, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity and anaphylactic reactions have been reported with use. Delayed reactions (up to 20 days after infusion) in previously untreated patients may also occur. Due to potential for allergic reactions, the initial ~10-20 administrations should be performed under appropriate medical supervision. Hypersensitivity reactions may be associated with factor IX inhibitor development; patients experiencing allergic reactions should be evaluated for factor IX inhibitors (WFH, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombotic events: Observe closely for signs or symptoms of intravascular coagulation or thrombosis. Use with caution when administering to patients with liver disease, postoperatively, neonates, or patients at risk of thromboembolic phenomena, disseminated intravascular coagulation or patients with signs of fibrinolysis due to the potential risk of thromboembolic complications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with extreme caution in patients with hepatic impairment; may be at increased risk of developing thrombosis or DIC.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heparin: Some products may contain heparin. Use with caution in patients with a history of heparin-induced thrombocytopenia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex: Some product packaging may contain natural rubber latex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Products do not contain therapeutic levels of factor VII and should not be used for the treatment of factor VII deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F169663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminocaproic Acid: May enhance the adverse/toxic effect of Factor IX Complex (Human). Specifically, use of this combination may increase the risk of thrombosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F169665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7281044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Bebulin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200-1200 unit (1): $1.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Bebulin VH Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200-1200 unit (1): $1.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Profilnine SD Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 unit (1): $1.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 unit (1): $1.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1500 unit (1): $1.19",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F169666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Levels of factor IX; PT, PTT; INR (when used for warfarin reversal); signs and symptoms of hypersensitivity reactions, DIC, thrombosis",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F169669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Average normal factor IX levels are 50% to 150%; patients with severe hemophilia B will have factor IX  levels &lt;1%, often undetectable. Moderate forms of the disease have levels of 1% to 5% while some mild cases may have 5% to 49% of normal factor IX.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alphanine SD (BR, HK, MY, SG, TW);",
"     </li>",
"     <li>",
"      Bebulin S-Tim 4 (AT);",
"     </li>",
"     <li>",
"      Bebulin Team 4 (RU);",
"     </li>",
"     <li>",
"      Bebulin TIM 4 (HN);",
"     </li>",
"     <li>",
"      Benefix (AR, AT, AU, BE, BG, BR, CH, CN, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IT, NL, NO, PT, RU, SE, TR);",
"     </li>",
"     <li>",
"      Betafact (IL);",
"     </li>",
"     <li>",
"      Facnyne (KP);",
"     </li>",
"     <li>",
"      Factor IX S-TIM (DE);",
"     </li>",
"     <li>",
"      Haemosolvex (ZA);",
"     </li>",
"     <li>",
"      Immunine (DE, SE, TH);",
"     </li>",
"     <li>",
"      Inmunine (VE);",
"     </li>",
"     <li>",
"      MonoFIX-VF (AU, HK);",
"     </li>",
"     <li>",
"      Mononine (BE, CZ, DE, FR, GB, IE, NL, SE);",
"     </li>",
"     <li>",
"      Nonafact (AT, BE, BG, CH, CZ, DE, DK, ES, FI, FR, GB, GR, HN, IE, IT, NL, NO, PT, RU, SE, TR);",
"     </li>",
"     <li>",
"      Octafix (FR);",
"     </li>",
"     <li>",
"      Octanine F (UY);",
"     </li>",
"     <li>",
"      Profilnine SD (MY, SG, TH);",
"     </li>",
"     <li>",
"      Proplex T (ID);",
"     </li>",
"     <li>",
"      Prothrombinex-VF (NZ);",
"     </li>",
"     <li>",
"      Replenine VF (IL, MY, SG);",
"     </li>",
"     <li>",
"      Replenine-VF (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F169657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replaces deficient clotting factor including factor X; hemophilia B, or Christmas disease, is an X-linked recessively inherited disorder of blood coagulation characterized by insufficient or abnormal synthesis of the clotting protein factor IX. Factor IX is a vitamin K-dependent coagulation factor which is synthesized in the liver. Factor IX is activated by factor XIa in the intrinsic coagulation pathway. Activated factor IX (IXa), in combination with factor VII:C, activates factor X to Xa, resulting ultimately in the conversion of prothrombin to thrombin and the formation of a fibrin clot. The infusion of exogenous factor IX to replace the deficiency present in hemophilia B temporarily restores hemostasis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F169673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Half-life elimination: IX component: ~24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baker RI, Coughlin PB, Gallus AS, et al, &ldquo;Warfarin Reversal: Consensus Guidelines, on Behalf of the Australasian Society of Thrombosis and Haemostasis,&rdquo;",
"      <i>",
"       Med J Aust,",
"      </i>",
"      2004, 181(9):492-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/30/18919/abstract-text/15516194/pubmed\" id=\"15516194\" target=\"_blank\">",
"        15516194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chong CT, Lew TWK, Kuperan P, et al, &ldquo;Rapid Reversal of Coagulopathy in Warfarin-Related Intracranial Haemorrhages With Prothombin Complex Concentrates,&rdquo;",
"      <i>",
"       Anaesth Intensive Care",
"      </i>",
"      , 2010, 38(3):474-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/30/18919/abstract-text/20514955/pubmed\" id=\"20514955\" target=\"_blank\">",
"        20514955",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/30/18919/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hellstern P, Halbmayer WM, K&ouml;hler M, et al, &ldquo;Prothrombin Complex Concentrates: Indications, Contraindications, and Risks: A Task Force Summary,&rdquo;",
"      <i>",
"       Thromb Res",
"      </i>",
"      , 1999, 95(4 Suppl 1):3-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/30/18919/abstract-text/10499902/pubmed\" id=\"10499902\" target=\"_blank\">",
"        10499902",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holland L, Warkentin TE, Refaai M, et al, &ldquo;Suboptimal Effect of a Three-Factor Prothrombin Complex Concentrate (Profilnine-SD) in Correcting Supratherapeutic International Normalized Ratio Due to Warfarin Overdose,&rdquo;",
"      <i>",
"       Transfusion",
"      </i>",
"      , 2009, 49(6):1171-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/30/18919/abstract-text/19210325/pubmed\" id=\"19210325\" target=\"_blank\">",
"        19210325",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee JW, &ldquo;Von Willebrand Disease, Hemophilia A and B, and Other Factor Deficiencies,&rdquo;",
"      <i>",
"       Int Anesthesiol Clin",
"      </i>",
"      , 2004, 42(3):59-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/30/18919/abstract-text/15205640/pubmed\" id=\"15205640\" target=\"_blank\">",
"        15205640",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liumbruno G, Bennardello F, Lattanzio A, et al, &ldquo;Recommendations for the Use of Antithrombin Concentrates and Prothrombin Complex Concentrates,&rdquo;",
"      <i>",
"       Blood Transfus",
"      </i>",
"      , 2009, 7(4):325-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/30/18919/abstract-text/20011645/pubmed\" id=\"20011645\" target=\"_blank\">",
"        20011645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lusher JM, &ldquo;Thrombogenicity Associated With Factor IX Complex Concentrates,&rdquo;",
"      <i>",
"       Semin Hematol",
"      </i>",
"      , 1991, 28(3 Suppl 6):3-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Makris M and Watson HG, &ldquo;The Management of Coumarin-Induced Over-Anticoagulation Annotation,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2001, 114(2):271-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/30/18919/abstract-text/11529844/pubmed\" id=\"11529844\" target=\"_blank\">",
"        11529844",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Makris M, Greaves M, Phillips WS, et al, &ldquo;Emergency Oral Anticoagulant Reversal: The Relative Efficacy of Infusions of Fresh Frozen Plasma and Clotting Factor Concentrate on Correction of the Coagulopathy,&rdquo;",
"      <i>",
"       Thromb Haemost",
"      </i>",
"      ,  1997, 77(3):477-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/30/18919/abstract-text/9065997/pubmed\" id=\"9065997\" target=\"_blank\">",
"        9065997",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Masotti L, Di Napoli M, Godoy DA, et al, &ldquo;The Practical Management of Intracerebral Hemorrhage Associated With Oral Anticoagulant Therapy,&rdquo;",
"      <i>",
"       Int Stroke J",
"      </i>",
"      , 2001, 6(3):228-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/30/18919/abstract-text/21557810/pubmed\" id=\"21557810\" target=\"_blank\">",
"        21557810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgenstern LB, Hemphill JC, Anderson C, et al, \"Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association,\"",
"      <i>",
"       Stroke",
"      </i>",
"      , 2010, 41(9):2108-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/30/18919/abstract-text/20651276/pubmed\" id=\"20651276\" target=\"_blank\">",
"        20651276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Hemophilia Foundation, &ldquo;Guidelines for Emergency Department Management of Individuals with Hemophilia,&rdquo; 2006. Available at  file://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/175.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Hemophilia Foundation, &ldquo;MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders,&rdquo; 2010. Available at  file://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/masac190.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Hemophilia Foundation, &ldquo;MASAC Recommendations Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding),&rdquo; 2007. Available at  file://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/masac179.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Preston FE, Laidlaw ST, Sampson B, et al, &ldquo;Rapid Reversal of Oral Anticoagulation With Warfarin by a Prothrombin Complex Concentrate (Beriplex): Efficacy and Safety in 42 Patients,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2002, 116(3):619-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/30/18919/abstract-text/11849221/pubmed\" id=\"11849221\" target=\"_blank\">",
"        11849221",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Warren O and Simon B. &ldquo;Massive, Fatal, Intracardiac Thrombosis Associated with Prothrombin Complex Concentrate,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2009, 53(6):758-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/30/18919/abstract-text/19181420/pubmed\" id=\"19181420\" target=\"_blank\">",
"        19181420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      World Federation of Hemophilia, &ldquo;Guidelines for the Management of Hemophilia,&rdquo; 2005. Available at  file://www.wfh.org/2/docs/Publications/Diagnosis_and_Treatment/Guidelines_Mng_Hemophilia.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yasaka M, Sakata T, Naritomi H, et al, &ldquo;Optimal Dose of Prothrombin Complex Concentrate for Acute Reversal of Oral Anticoagulation,&rdquo;",
"      <i>",
"       Thromb Res",
"      </i>",
"      , 2005, 115(6):455-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/30/18919/abstract-text/15792675/pubmed\" id=\"15792675\" target=\"_blank\">",
"        15792675",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10085 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-C815FD8784-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_30_18919=[""].join("\n");
var outline_f18_30_18919=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169679\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169690\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169681\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169686\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169682\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881408\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881409\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169668\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169654\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169671\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169670\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5662083\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14634078\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169688\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169674\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169658\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299308\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169663\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169665\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7281044\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323143\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169666\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169669\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539858\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169657\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169673\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10085\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10085|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/3/26676?source=related_link\">",
"      Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/27/8630?source=related_link\">",
"      Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_30_18920="Toxic megacolon";
var content_f18_30_18920=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Toxic megacolon",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/30/18920/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/30/18920/contributors\">",
"     Sunil G Sheth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/30/18920/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/30/18920/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/30/18920/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/30/18920/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/30/18920/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/30/18920/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/30/18920/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxic megacolon is a potentially lethal complication of inflammatory bowel disease (IBD) or infectious colitis that is characterized by total or segmental nonobstructive colonic dilatation plus systemic toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Colonic dilatation is also observed in patients with congenital megacolon (Hirschsprung's disease), idiopathic or acquired megacolon occurring with chronic constipation of any etiology, and intestinal pseudoobstruction, a manifestation of diffuse gastrointestinal dysmotility of various causes. However, the lack of systemic toxicity distinguishes these presentations from true toxic megacolon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/50/22311?source=see_link\">",
"     \"Acute colonic pseudo-obstruction (Ogilvie's syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise incidence of toxic megacolon is unknown. The incidence in ulcerative colitis and Crohn's disease was approximately 1 to 5 percent two decades ago [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/4\">",
"     4",
"    </a>",
"    ], but has gradually decreased because of earlier recognition and intensive management of severe colitis. Clinically symptomatic Clostridium difficile infection occurs in approximately 1 percent of all hospitalized patients; a few of these may develop severe colitis with toxic megacolon [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most commonly recognized as a complication of IBD, toxic megacolon may also occur with infectious colitides of diverse etiology, ischemic colitis, volvulus, diverticulitis, and obstructive colon cancer (",
"    <a class=\"graphic graphic_table graphicRef72629 \" href=\"UTD.htm?32/47/33531\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical features that suggest IBD as a cause of toxic megacolon include a preceding history of diarrhea, bloody stools, abdominal pain, perianal disease, or extraintestinal manifestations such as arthritis, iritis, skin disease, or liver disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"       \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Risk factors for the development of severe colitis in patients with C. difficile infection include malignancy, chronic obstructive pulmonary disease, immunosuppressive therapy, renal failure, or exposure to antiperistaltic medications or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/5\">",
"       5",
"      </a>",
"      ]. Toxic megacolon has been described in patients with recurrent C. difficile [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Salmonella, Shigella, and Campylobacter colitis are very rarely complicated by toxic dilatation, and can usually be differentiated from IBD by histology and endoscopic biopsy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/9\">",
"       9",
"      </a>",
"      ]. Toxic megacolon may also complicate hemorrhagic colitis and hemolytic-uremic syndrome secondary to infection with E. coli 0157 [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fewer than 3 percent of patients with amoebic colitis have a fulminant clinical course, and a small fraction develop toxic megacolon. The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"       loperamide",
"      </a>",
"      in amoebic colitis may precipitate toxic megacolon [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with HIV infection or AIDS, cytomegalovirus (CMV) colitis is the leading cause of toxic megacolon and emergency laparotomy; this usually occurs in the setting of disseminated CMV infection. CMV infection of the colon may also precipitate toxic megacolon in patients with IBD [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/12\">",
"       12",
"      </a>",
"      ]. In one series, for example, 6 of 46 resected colons in patients with ulcerative colitis showed evidence of CMV infection; 5 of these 6 patients had toxic dilatation compared with only 2 of the remaining 40 patients without CMV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of pathogenic mechanisms probably contribute to the development of toxic megacolon in patients with IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/1\">",
"     1",
"    </a>",
"    ]. One possible mechanism is that mucosal inflammation leads sequentially to the release of inflammatory mediators and bacterial products, increased inducible nitric oxide synthase, generation of excessive nitric oxide, and colonic dilatation.",
"   </p>",
"   <p>",
"    Extension of the mucosal inflammation may also be important. In contrast to typical ulcerative colitis in which the inflammatory response is limited to the mucosa, toxic megacolon is characterized by severe inflammation of the smooth muscle layer which paralyzes the colonic smooth muscle, thereby leading to dilatation. The extent of dilatation appears to be correlated with the depth of inflammation and ulceration. Damage to the myenteric plexus of the colon is not a consistent finding.",
"   </p>",
"   <p>",
"    A number of precipitating factors have been identified. These include hypokalemia, antimotility agents, opiates, anticholinergics, antidepressants,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema, and colonoscopy. Barium enema or colonoscopy may cause distention, which further impairs the blood supply to the colon wall and increases the mucosal uptake of bacterial products. Discontinuing or rapid tapering of corticosteroids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , or 5-ASA compounds also may contribute to the development of megacolon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nitric oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitric oxide (NO) is a known inhibitor of smooth muscle tone that may be involved in the pathogenesis of toxic megacolon [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/1\">",
"     1",
"    </a>",
"    ]. NO generation occurs in macrophages and smooth muscle cells in the inflamed colon. One group studied full thickness colonic wall specimens of patients who underwent surgery for toxic megacolon, active pancolonic ulcerative colitis, or nonobstructive colonic neoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/14\">",
"     14",
"    </a>",
"    ]. Both the amount and activity of inducible NO synthase were significantly increased in the muscular layer in patients with toxic megacolon compared with the other groups, particularly in the most dilated colonic segments.",
"   </p>",
"   <p>",
"    These findings were supported by an animal study which demonstrated that inducible NO synthase was decreased after bowel decontamination with oral nonabsorbable broad spectrum antibiotics, as well as after administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ; these maneuvers also prevented colonic dilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, the diameter of the colon, contractility of the colonic muscle, and intracolonic pressure improved after pharmacologic blockade with NO synthase inhibitors, suggesting a possible treatment for patients with toxic megacolon. Enema therapy with a nitric oxide synthase inhibitor was associated with clinical improvement in a patient with toxic megacolon due to ulcerative colitis providing in-vivo evidence for the role of nitric oxide in human toxic megacolon [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gross pathologic features of fulminant colitis and toxic megacolon are similar in both ulcerative colitis and Crohn's disease, with marked dilatation of the colon, thinning of the bowel wall, and deep ulcers. The histologic hallmark is acute inflammation in all layers of the colon with varying degrees of degeneration, necrosis, and replacement by granulation tissue infiltrated by histiocytes, neutrophils, lymphocytes, and plasma cells. The muscle fibers are frequently shortened and rounded with aggregates of eosinophilic cytoplasm. The preservation of colonic submucosal and myenteric plexi is a common feature and is strong evidence against a neuropathic process [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathologic appearance of toxic megacolon associated with other disorders is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In toxic megacolon secondary to C. difficile (or, rarely, ischemia), the characteristic pathologic features include diffuse ulcerations, raised mucosal nodules, yellowish-white superficial plaques with normal intervening mucosa (typical \"pseudomembrane\" appearance), and extensive denudation (",
"      <a class=\"graphic graphic_picture graphicRef62422 \" href=\"UTD.htm?4/15/4337\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Similar findings may also be seen in fulminant amoebic colitis, in addition to the characteristic \"wet-blotting paper\" appearance of the involved bowel segments, punched-out ulcers, and presence of trophozoites in biopsy specimens.",
"     </li>",
"     <li>",
"      CMV colitis is characterized by the presence of inclusion bodies in biopsy specimens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxic megacolon affects all ages and both sexes. Patients with IBD are at the highest risk for developing this complication early in their disease, not infrequently at initial presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/3\">",
"     3",
"    </a>",
"    ]. Of those patients with IBD who develop toxic megacolon, approximately 30 percent develop toxic dilatation within three months of diagnosis, and approximately 60 percent within the first three years.",
"   </p>",
"   <p>",
"    Signs and symptoms of acute colitis that are frequently resistant to therapy are often present for at least one week prior to the onset of acute dilatation. Severe bloody diarrhea is the most common presenting symptom, while improvement of diarrhea may herald the onset of megacolon. One study of patients with C. difficile colitis and toxic megacolon found that diarrhea was a complaint in 100 percent of cases, malaise in 91 percent, and abdominal pain and distention in 82 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physical examination invariably reveals a toxic appearing patient with altered sensorium, tachycardia, fever, postural hypotension, lower abdominal distension and tenderness, with or without signs of localized or generalized peritonitis. However, large doses of steroids, analgesics, or a clouded sensorium may mask the signs or symptoms of toxic megacolon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of toxic megacolon should be considered in all patients presenting with abdominal distension and acute or chronic diarrhea. The diagnosis is clinical, based upon the finding of an enlarged dilated colon accompanied by severe systemic toxicity. The initial evaluation should be aimed at establishing the diagnosis of toxic megacolon and at determining the underlying etiology to help institute specific therapeutic measures.",
"   </p>",
"   <p>",
"    A thorough history is crucial. Knowledge of prior attacks of IBD, the extent and type of disease, details of prior therapy, extraintestinal manifestations of IBD, recent travel, occupational exposure (eg, day care workers), antibiotic or chemotherapy use, use of antimotility agents, and",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    status are very helpful.",
"   </p>",
"   <p>",
"    Plain abdominal films should be obtained immediately. In addition, stool specimens should be sent for culture, microscopic analysis, and C. difficile toxin.",
"   </p>",
"   <p>",
"    The most widely used criteria for the clinical diagnosis of toxic megacolon are [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiographic evidence of colonic distension",
"     </li>",
"     <li>",
"      PLUS at least three of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fever &gt;38&ordm;C",
"     </li>",
"     <li>",
"      Heart rate &gt;120",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"     </li>",
"     <li>",
"      Neutrophilic leukocytosis",
"      <span class=\"nowrap\">",
"       &gt;10,500/microL",
"      </span>",
"     </li>",
"     <li>",
"      Anemia",
"     </li>",
"     <li>",
"      PLUS at least one of the following:",
"     </li>",
"     <li>",
"      Dehydration",
"     </li>",
"     <li>",
"      Altered sensorium",
"     </li>",
"     <li>",
"      Electrolyte disturbances",
"     </li>",
"     <li>",
"      Hypotension",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain abdominal radiographs are critical for diagnosing toxic megacolon and for following its course. There are several typical features (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59217 \" href=\"UTD.htm?10/11/10416\">",
"     image 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The transverse or right colon is usually the most dilated, frequently greater than 6 cm and occasionally up to 15 cm on supine films [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/2\">",
"       2",
"      </a>",
"      ]. The descending colon less frequently, and the sigmoid colon and rectum rarely also appear distended. Repositioning of the patient results in redistribution of air in the colon, thereby causing variation in the location of maximal air; thus, the location of air is not as important as the degree of dilatation.",
"     </li>",
"     <li>",
"      Multiple air-fluid levels in the colon are common; the normal colonic haustral pattern is either absent or severely disturbed.",
"     </li>",
"     <li>",
"      Deep mucosal ulcerations may appear as air-filled crevices between large pseudopolypoid projections extending into the colonic lumen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It must be emphasized that even though a maximum colonic diameter greater than 6 cm is consistent with the diagnosis of megacolon, the overall clinical condition of the patient is more important than the absolute width of the dilated segment. Colonic dilatation and systemic toxicity are seen in patients with acute colonic obstruction from volvulus, pelvic tumors, and intraluminal obstructing tumors. In these patients a history of acute or chronic diarrhea is unusual and air is absent in the colon below the point of obstruction.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     Barium",
"    </a>",
"    enema or colonoscopy is often required to diagnose the level and type of obstruction.",
"   </p>",
"   <p>",
"    Ultrasonography and computed tomography (CT) may aid in overall management. High resolution ultrasonography can be used to accurately determine the extent and activity of severe ulcerative colitis and assess the response to therapy; it may also permit the early detection of toxic megacolon [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT scanning may occasionally be of value in determining the etiology of megacolon. In toxic megacolon due to C. difficile infection, for example, diffuse colonic thickening is a very sensitive (but not specific) finding [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/19\">",
"     19",
"    </a>",
"    ]. A CT scan may be particularly useful in patients with AIDS who may have several intercurrent intraabdominal processes.",
"   </p>",
"   <p>",
"    CT scanning is also especially useful for identifying complications of megacolon, such as perforation or vascular compromise, and is helpful for excluding other causes of colonic distension, such as mechanical obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be multiple, nonspecific laboratory abnormalities associated with toxic megacolon:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anemia related to blood loss and leukocytosis with a left shift occurs frequently, except in patients with AIDS in whom neutropenia may supervene.",
"     </li>",
"     <li>",
"      Electrolyte disturbances are extremely common and may be multifactorial. As an example, the inflamed colon loses its capacity to reabsorb salt and water. In addition, the rate of potassium excretion into the lumen may be markedly increased due to inflammatory diarrhea and steroid use. Metabolic alkalosis secondary to volume depletion and potassium loss is associated with a poor prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/21\">",
"       21",
"      </a>",
"      ]. Metabolic acidosis suggests the presence of ischemic colitis.",
"     </li>",
"     <li>",
"      Hypoalbuminemia may not be a prominent feature in the early stages of illness, but a serum albumin concentration below 3",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      develops eventually in approximately 75 percent of cases due to protein loss and decreased hepatic synthesis due to chronic inflammation and malnutrition.",
"     </li>",
"     <li>",
"      The erythrocyte sedimentation rate and serum C-reactive protein are usually increased.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited endoscopy without bowel preparation is useful if IBD has not previously been diagnosed or an infective process is suspected, particularly CMV or acute bacillary dysentery. However, a limited sigmoidoscopy can miss CMV inclusion bodies since ulcers may be limited to the ascending colon in up to 40 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/22\">",
"     22",
"    </a>",
"    ]. A more limited examination of the rectum may also allow a rapid diagnosis of pseudomembranous colitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link&amp;anchor=H20#H20\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\", section on 'Endoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A full colonoscopy is extremely",
"    <strong>",
"     risky",
"    </strong>",
"    in patients with toxic megacolon; this procedure can easily lead to colonic perforation and we feel that it should generally be avoided. One report, however, suggested that colonoscopy was safe in patients with severe ulcerative colitis and helped the clinician make therapeutic decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both limited endoscopy and full colonoscopy should be performed with extreme caution and minimal or no air insufflation should be used to avoid worsening ileus or distention and perforation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main goal of treatment is to reduce the severity of colitis in order to restore normal colonic motility and decrease the likelihood of perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/1\">",
"     1",
"    </a>",
"    ]. The initial therapy is medical, which is successful in preventing surgery in up to 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/2\">",
"     2",
"    </a>",
"    ]. However, a surgical consultation should be obtained upon admission, and the patient should be evaluated daily by both the medical and surgical team.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Medical therapy in patients with IBD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are placed at complete bowel rest and a nasogastric tube (or long intestinal tube) is inserted to decompress the gastrointestinal tract. Enteral feeding is begun as soon as the patient shows signs of improvement to hasten mucosal healing and stimulate normal motility. The patient should be monitored in the intensive care unit with frequent examinations by the nursing and medical staff to assess for signs of deterioration. Complete blood counts, electrolytes, and serial abdominal plain films are reviewed every 12 hours initially and then daily as the patient improves. Anemia, dehydration, and electrolyte deficits, particularly hypokalemia, may aggravate colonic dysmotility and should be treated aggressively.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     Total parenteral nutrition",
"    </a>",
"    (TPN) is of limited value in patients with severe IBD or toxic megacolon from any cause. It offers no proven benefit in terms of avoiding surgery or decreasing hospital stay in patients with acute colitis due to ulcerative colitis. In a prospective controlled study of 36 patients, for example, there was no significant improvement in those receiving TPN with total bowel rest; 6 came to surgery and 11 responded medically in a mean time of 24 days in the control group, while 9 came to surgery and 10 responded medically in a mean time of 21 days in the TPN group [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All antimotility agents, opiates, and anticholinergics should be discontinued. Patients should be given prophylaxis for both gastric stress ulcerations and deep venous thrombosis (pneumatic compression stockings). Broad spectrum antibiotics are recommended to reduce septic complications and in anticipation of peritonitis resulting from perforation. We generally use ampicillin-gentamicin-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or a third-generation cephalosporin with metronidazole.",
"   </p>",
"   <p>",
"    Intravenous corticosteroids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    100 mg or equivalent every six to eight hours or by continuous infusion) should be given to all patients for the treatment of underlying ulcerative colitis or Crohn's disease; this does not increase the risk of perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/17\">",
"     17",
"    </a>",
"    ]. As previously mentioned,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    has been shown in experimental studies to decrease the colonic diameter by diminishing the expression of inducible NO synthase [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/15\">",
"     15",
"    </a>",
"    ]. Some clinicians prefer to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    because of its lower sodium retaining and potassium wasting properties, while others prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    since the parenteral dose is equal to the oral dose. Steroids are",
"    <strong>",
"     not",
"    </strong>",
"    used in toxic megacolon due to C. difficile colitis or infective colitis if the etiology has been established.",
"   </p>",
"   <p>",
"    Some authorities recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/62/2023?source=see_link\">",
"     adrenocorticotropic hormone",
"    </a>",
"    (ACTH) in patients who have not received steroids for at least 30 days; there is some evidence that it may be more beneficial than intravenous corticosteroids in the treatment of underlying ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/25\">",
"     25",
"    </a>",
"    ]. Although initially popular, ACTH is now infrequently used.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    and 5-ASA compounds have",
"    <strong>",
"     no role",
"    </strong>",
"    in patients with toxic megacolon due to IBD and should be initiated only after the attack begins to resolve. In some instances, a flare may actually coincide with the initiation of certain 5-ASA compounds.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is useful in the treatment of severe colitis refractory to steroid therapy, but the experience in toxic megacolon is limited.",
"   </p>",
"   <p>",
"    Some authors recommend intermittent rolling maneuvers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/26\">",
"     26",
"    </a>",
"    ] or the knee-elbow position [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/27\">",
"     27",
"    </a>",
"    ] to help redistribute gas in the colon and thereby promote decompression. These techniques are based upon the observation that when a patient is rolled from the supine to prone position or adopts a knee-elbow position, gas rises to the distal",
"    <span class=\"nowrap\">",
"     colon/rectum",
"    </span>",
"    and is more easily expelled. In one uncontrolled study, all 19 patients with toxic megacolon complicating IBD who were treated with the usual medical therapy and rolling maneuvers achieved decompression within 1 to 13 days [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/26\">",
"     26",
"    </a>",
"    ]. This technique may be particularly useful in patients in whom the \"toxicity\" is controlled but colonic dilatation persists.",
"   </p>",
"   <p>",
"    Medical therapy is successful when the patient appears to be less toxic, fluid and transfusion requirements decrease, abdominal and colonic dilatation begin to resolve, and laboratory parameters improve. On the other hand, persistent fever after 48 to 72 hours of steroid therapy should raise the possibility of localized perforation or abscess.",
"   </p>",
"   <p>",
"    Free perforation, massive hemorrhage, increasing transfusion requirements, worsening signs of toxicity, and progression of colonic dilatation are absolute indications for surgery. In addition, most surgical studies recommend colectomy if there is persistent colonic distention after 48 to 72 hours. However, we recommend prolongation of medical therapy up to seven days if the patient appears to be clinically improving despite persistent megacolon and there is no perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/26,28\">",
"     26,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Medical therapy in patients with other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the general maneuvers for intensive care unit monitoring cited above (including a nasogastric tube for decompression), medical therapy in patients with toxic megacolon due to diseases other than IBD may include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with toxic megacolon due to severe C. difficile colitis, the first step is to stop the offending antibiotic, followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      500 mg four times daily orally or via a nasogastric tube and intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      at a dose of 500 mg every eight hours. Fecal concentrations of metronidazole in the therapeutic range are achieved with this regimen because of biliary excretion of the drug [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/29\">",
"       29",
"      </a>",
"      ]. In contrast, intravenous vancomycin has",
"      <strong>",
"       no",
"      </strong>",
"      effect on C. difficile colitis since the antibiotic is not excreted into the colon.",
"      <br/>",
"      <br/>",
"      Colectomy is reserved for patients who do not improve within 48 to 72 hours, or who show evidence of localized perforation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/30\">",
"       30",
"      </a>",
"      ]. Patients with azotemia, lactic acidosis, or white blood cell counts above",
"      <span class=\"nowrap\">",
"       20,000/cu",
"      </span>",
"      ml are more likely to require emergency colectomy for fulminant C. difficile infection. In a small series of six patients with an acute abdomen secondary to C. difficile colitis, two who developed dilated colons were successfully decompressed by colonoscopy, obviating the need for surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with HIV infection who develop toxic megacolon, an aggressive search for treatable infectious and noninfectious causes is warranted, including early limited endoscopy and imaging studies. Patients with CMV colitis or C. difficile infection respond poorly to medical therapy and often require emergent laparotomy with subtotal colectomy and ileostomy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. In one report, however, four of five such patients died despite emergency colectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/32\">",
"       32",
"      </a>",
"      ]. Critically ill patients who would not be able to withstand surgery, as well as patients with terminal AIDS, could possibly be managed by careful colonic decompression, antibiotics, and supportive therapy.",
"     </li>",
"     <li>",
"      Fulminant colitis during pregnancy with or without toxic megacolon is especially difficult because the gravid uterus impairs a proper abdominal examination, and diagnostic radiation poses hazards to the fetus [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/34\">",
"       34",
"      </a>",
"      ]. In addition, laboratory tests such as hemoglobin and serum albumin concentrations fall during pregnancy, while the erythrocyte sedimentation rate and serum C-reactive protein levels rise; thus, these tests are not reliable measures of disease activity. High dose intravenous steroid therapy (the equivalent of 60 to 120",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) results in resolution of 75 percent of cases of fulminant colitis; the remainder requiring urgent colectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subtotal colectomy with end-ileostomy is the procedure of choice for urgent or emergent surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/37\">",
"     37",
"    </a>",
"    ]. This technique has a lower morbidity and mortality than single stage proctocolectomy and allows subsequent re-anastomosis in most patients. Early surgery in patients without evidence of perforation results in much lower mortality than colectomy performed after colonic perforation has occurred (2 to 8 versus 40 percent or more) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"     \"Surgical management of ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality rates in patients who develop toxic megacolon are variable. Before 1976, the death rate in 604 cases of toxic megacolon was 27 percent (43 of 160) for those treated medically, and 19 percent in 444 patients who underwent surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/39\">",
"     39",
"    </a>",
"    ]. The mortality rates dropped dramatically to between 0 and 2 percent in patients with IBD, probably related to a variety of factors including early recognition of toxic megacolon, better intensive medical management, earlier surgical intervention, and superior postoperative care [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/38\">",
"     38",
"    </a>",
"    ]. Variations in mortality rates are also related to the medical or surgical biases of the treating physicians.",
"   </p>",
"   <p>",
"    Two studies from the medical literature have shown that 68 to 75 percent of cases of toxic megacolon treated medically did not require a colectomy later, and have remained in remission for up to six years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/26,28\">",
"     26,28",
"    </a>",
"    ]. Surgical studies report up to a 50 percent rate of future colectomy in patients with toxic megacolon who had presumably responded to medical treatment alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/2,40\">",
"     2,40",
"    </a>",
"    ]. Early surgery decreased the mortality rate from 22 to 1.2 percent in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A literature review of patients with toxic megacolon secondary to C. difficile infection between 1968 and 1992 found an overall mortality of 31 to 35 percent, 42 percent for those treated with surgery and 18 percent for those treated medically [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/6\">",
"     6",
"    </a>",
"    ]. In two later studies, the overall mortality from severe C. difficile",
"    <span class=\"nowrap\">",
"     colitis/toxic",
"    </span>",
"    megacolon was 64 to 67 percent, 71 to 100 percent for surgically treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. These studies suggest that patients who develop toxic megacolon during C. difficile infection can survive with medical therapy alone, and surgery may offer a very limited benefit. On the other hand, surgery should not be extensively delayed in acutely ill patients.",
"   </p>",
"   <p>",
"    It is generally accepted that colonic dilatation due to infective colitis has a better prognosis than toxic megacolon occurring in patients with IBD; however, this conclusion is largely based upon small studies or case reports. The prognosis is particularly good when colonic dilatation complicates acute self-limited colitis, and is treated aggressively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18920/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxic megacolon is a potentially lethal complication of inflammatory bowel disease (IBD) or infectious colitis that is characterized by total or segmental nonobstructive colonic dilatation plus systemic toxicity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Toxic megacolon may occur as a complication of IBD, infectious colitides of diverse etiology, ischemic colitis, volvulus, diverticulitis, and obstructive colon cancer. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Of those patients with IBD who develop toxic megacolon, approximately 30 percent develop toxic dilatation within three months of diagnosis, and approximately 60 percent within the first three years. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe bloody diarrhea is the most common presenting symptom. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiographic findings on plain abdominal films that are typical for toxic megacolon include dilatation of the right colon greater than 6 centimeters, dilatation of the transverse colon; absence of normal colonic haustral markings, and air-filled crevices between large pseudopolypoid projections extending into the colonic lumen. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medical therapy is the first line of treatment for patients with IBD and toxic megacolon and includes fluid resuscitation and correction of laboratory abnormalities, administration of broad spectrum antibiotics, intravenous corticosteroids, complete bowel rest, bowel decompression with a nasogastric or long intestinal tube, and a surgical consultation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medical therapy is the first line of treatment for patients with toxic colon from C. difficile and includes fluid resuscitation and correction of laboratory abnormalities, discontinuation of the offending antibiotic, oral or tube administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      and intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      , complete bowel rest, bowel decompression with a nasogastric or long intestinal tube, and a surgical consultation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The operative procedure of choice is a subtotal colectomy with end-ileostomy and is reserved for patients who do not improve on medical management. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/1\">",
"      Sheth SG, LaMont JT. Toxic megacolon. Lancet 1998; 351:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/2\">",
"      Fazio VW. Toxic megacolon in ulcerative colitis and Crohn's colitis. Clin Gastroenterol 1980; 9:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/3\">",
"      Jalan KN, Sircus W, Card WI, et al. An experience of ulcerative colitis. I. Toxic dilation in 55 cases. Gastroenterology 1969; 57:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/4\">",
"      Grieco MB, Bordan DL, Geiss AC, Beil AR Jr. Toxic megacolon complicating Crohn's colitis. Ann Surg 1980; 191:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/5\">",
"      Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum 1995; 38:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/6\">",
"      Trudel JL, Desch&ecirc;nes M, Mayrand S, Barkun AN. Toxic megacolon complicating pseudomembranous enterocolitis. Dis Colon Rectum 1995; 38:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/7\">",
"      Berman L, Carling T, Fitzgerald TN, et al. Defining surgical therapy for pseudomembranous colitis with toxic megacolon. J Clin Gastroenterol 2008; 42:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/8\">",
"      Louie TJ. Treatment of first recurrences of Clostridium difficile-associated disease: waiting for new treatment options. Clin Infect Dis 2006; 42:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/9\">",
"      Surawicz CM, Haggitt RC, Husseman M, McFarland LV. Mucosal biopsy diagnosis of colitis: acute self-limited colitis and idiopathic inflammatory bowel disease. Gastroenterology 1994; 107:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/10\">",
"      Nayar DM, Vetrivel S, McElroy J, et al. Toxic megacolon complicating Escherichia coli O157 infection. J Infect 2006; 52:e103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/11\">",
"      McGregor A, Brown M, Thway K, Wright SG. Fulminant amoebic colitis following loperamide use. J Travel Med 2007; 14:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/12\">",
"      Hommes DW, Sterringa G, van Deventer SJ, et al. The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis 2004; 10:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/13\">",
"      Cooper HS, Raffensperger EC, Jonas L, Fitts WT Jr. Cytomegalovirus inclusions in patients with ulcerative colitis and toxic dilation requiring colonic resection. Gastroenterology 1977; 72:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/14\">",
"      Mourelle M, Casellas F, Guarner F, et al. Induction of nitric oxide synthase in colonic smooth muscle from patients with toxic megacolon. Gastroenterology 1995; 109:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/15\">",
"      Mourelle M, Vilaseca J, Guarner F, et al. Toxic dilatation of colon in a rat model of colitis is linked to an inducible form of nitric oxide synthase. Am J Physiol 1996; 270:G425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/16\">",
"      Schw&ouml;rer H, Bohn M, Waezsada SY, et al. Successful treatment of megacolon associated with colitis with a nitric oxide synthase inhibitor. Am J Gastroenterol 2001; 96:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/17\">",
"      Norland CC, Kirsner JB. Toxic dilatation of colon (toxic megacolon): etiology, treatment and prognosis in 42 patients. Medicine (Baltimore) 1969; 48:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/18\">",
"      Arienti V, Campieri M, Boriani L, et al. Management of severe ulcerative colitis with the help of high resolution ultrasonography. Am J Gastroenterol 1996; 91:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/19\">",
"      Mukai JK, Janower ML. Diagnosis of pseudomembranous colitis by computed tomography: a report of two patients. Can Assoc Radiol J 1987; 38:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/20\">",
"      Gan SI, Beck PL. A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol 2003; 98:2363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/21\">",
"      Caprilli R, Vernia P, Colaneri O, Torsoli A. Blood pH: a test for assessment of severity in proctocolitis. Gut 1976; 17:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/22\">",
"      Dieterich DT, Rahmin M. Cytomegalovirus colitis in AIDS: presentation in 44 patients and a review of the literature. J Acquir Immune Defic Syndr 1991; 4 Suppl 1:S29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/23\">",
"      Alemayehu G, J&auml;rnerot G. Colonoscopy during an attack of severe ulcerative colitis is a safe procedure and of great value in clinical decision making. Am J Gastroenterol 1991; 86:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/24\">",
"      Dickinson RJ, Ashton MG, Axon AT, et al. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology 1980; 79:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/25\">",
"      Meyers S, Sachar DB, Goldberg JD, Janowitz HD. Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. A prospective, randomized, double-blind clinical trial. Gastroenterology 1983; 85:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/26\">",
"      Present DH, Wolfson D, Gelernt IM, et al. Medical decompression of toxic megacolon by \"rolling\". A new technique of decompression with favorable long-term follow-up. J Clin Gastroenterol 1988; 10:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/27\">",
"      Panos MZ, Wood MJ, Asquith P. Toxic megacolon: the knee-elbow position relieves bowel distension. Gut 1993; 34:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/28\">",
"      Caprilli R, Vernia P, Latella G, Torsoli A. Early recognition of toxic megacolon. J Clin Gastroenterol 1987; 9:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/29\">",
"      Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/30\">",
"      Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/31\">",
"      Triadafilopoulos G, Hallstone AE. Acute abdomen as the first presentation of pseudomembranous colitis. Gastroenterology 1991; 101:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/32\">",
"      Beaugerie L, Ng&ocirc; Y, Goujard F, et al. Etiology and management of toxic megacolon in patients with human immunodeficiency virus infection. Gastroenterology 1994; 107:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/33\">",
"      Davidson T, Allen-Mersh TG, Miles AJ, et al. Emergency laparotomy in patients with AIDS. Br J Surg 1991; 78:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/34\">",
"      Boulton R, Hamilton M, Lewis A, et al. Fulminant ulcerative colitis in pregnancy. Am J Gastroenterol 1994; 89:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/35\">",
"      Truelove SC, Willoughby CP, Lee EG, Kettlewell MG. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978; 2:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/36\">",
"      Mathur, S, Agarwal, VP, Lewis, A, et al. Fulminant ulcerative colitis in late pregnancy. Eur J Gastroenterol Hepatol 1991; 3:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/37\">",
"      Ausch C, Madoff RD, Gnant M, et al. Aetiology and surgical management of toxic megacolon. Colorectal Dis 2006; 8:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/38\">",
"      Danovitch SH. Fulminant colitis and toxic megacolon. Gastroenterol Clin North Am 1989; 18:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/39\">",
"      Strauss RJ, Flint GW, Platt N, et al. The surgical management of toxic dilatation of the colon: a report of 28 cases and review of the literature. Ann Surg 1976; 184:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/40\">",
"      Greenstein AJ, Kark AE, Dreiling DA. Crohn's disease of the colon. III. Toxic dilatation of the colon in Crohn's colitis. Am J Gastroenterol 1975; 63:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/41\">",
"      Flatmark A, Fretheim B, Gjone E. Early colectomy in severe ulcerative colitis. Scand J Gastroenterol 1975; 10:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18920/abstract/42\">",
"      Snowden JA, Young MJ, McKendrick MW. Dilatation of the colon complicating acute self-limited colitis. Q J Med 1994; 87:55.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1381 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-6DAE62D42F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_30_18920=[""].join("\n");
var outline_f18_30_18920=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nitric oxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Medical therapy in patients with IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Medical therapy in patients with other disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/1381\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1381|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/11/10416\" title=\"diagnostic image 1\">",
"      Toxic megacolon in C diff",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1381|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/15/4337\" title=\"picture 1\">",
"      Pseudomembranous colitis Gross",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1381|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/47/33531\" title=\"table 1\">",
"      Causes of toxic megacolon",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/50/22311?source=related_link\">",
"      Acute colonic pseudo-obstruction (Ogilvie's syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=related_link\">",
"      Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=related_link\">",
"      Surgical management of ulcerative colitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_30_18921="Mechanisms of immune injury of the glomerulus";
var content_f18_30_18921=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mechanisms of immune injury of the glomerulus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/30/18921/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/30/18921/contributors\">",
"     William G Couser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/30/18921/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/30/18921/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/30/18921/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/30/18921/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/30/18921/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glomerular injury of immune origin is mediated by the actions of multiple elements of both the innate and adaptive immune systems, thereby resulting in diverse clinical and pathologic manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The immune events that occur following antigen exposure and lead to immune complex formation in glomeruli and T cell mediated injury are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40261?source=see_link\">",
"     \"Pathogenesis of tissue injury in glomerulonephritis\"",
"    </a>",
"    .) This topic reviews the glomerular response to immune injury and the mediators involved. A schematic depiction of the relationship between immune events, effector cells, mediator release, and eventual glomerular injury is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef52652 \" href=\"UTD.htm?5/47/5887\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When inflammatory changes occur, for example, glomerular hypercellularity is due to infiltrating hematopoietic cells (such as neutrophils and macrophages), proliferating glomerular cells, or both. These effector cells then induce other abnormalities, such as thrombosis, necrosis, and crescent formation, which, if extensive, may result in rapidly progressive renal insufficiency and nephritis. By comparison, noninflammatory lesions resulting from immune injury usually involve the podocyte as the major effector cell and are associated with a major functional change of the glomerulus (usually an increase in protein permeability), but without light microscopic evidence of damage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/4\">",
"     4",
"    </a>",
"    ]. This most commonly results in proteinuria and the nephrotic syndrome and may lead to glomerular sclerosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NONINFLAMMATORY MECHANISMS OF IMMUNE GLOMERULAR INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minimal change nephrotic",
"    <span class=\"nowrap\">",
"     syndrome/focal",
"    </span>",
"    segmental glomerulosclerosis",
"    <span class=\"nowrap\">",
"     (MCNS/FSGS)",
"    </span>",
"    and membranous nephropathy (MN) are characterized initially by dramatic increases in glomerular permeability in association with little or no structural abnormalities by light microscopy. The principal target of injury is the podocyte, and the diseases are among the podocytopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34601?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of minimal change disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=see_link\">",
"     \"Causes and diagnosis of membranous nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9304?source=see_link\">",
"     \"Biology of glomerular podocytes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENIC AGENTS IN PODOCYTOPATHIES OF IMMUNE ORIGIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of immune mediators that can directly induce podocyte dysfunction sufficiently to result in nephrotic-range proteinuria without inflammation have been identified, including T cell-derived factors, vasoactive agents, C5b-9, and cytokines like IL13 and cardiotropin-like cytokine 1 (CLC1) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Glomerular permeability factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;With",
"    <span class=\"nowrap\">",
"     MCNS/FSGS,",
"    </span>",
"    the existence of a non-immunoglobulin circulating permeability factor is postulated because of the following clinical observations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/5,7-9\">",
"     5,7-9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rapid recurrence of MCNS or FSGS in normal kidneys transplanted into some patients with these disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33722?source=see_link\">",
"       \"Focal segmental glomerulosclerosis in the transplanted kidney\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The ability of serum from some patients with FSGS who develop recurrent disease to increase the albumin reflection coefficient of isolated normal glomeruli in vitro [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rapid disease resolution when MCNS kidneys are placed in a normal environment [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional support for a role for permeability factors in some podocytopathies is provided by findings in animal models of glomerular disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In rodents, the administration of an unidentified permeability factor derived from T-cells of patients with active MCNS or administration of stem cells from patients with active MCNS or FSGS produces significant proteinuria in association with minimal glomerular abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Over-expression of the cytokine IL13, a 10,000 kD cytokine that is upregulated in T cells of children with steroid-sensitive nephrotic syndrome in relapse, also causes proteinuria and foot process effacement in rats [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. Details concerning this cytokine are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34601?source=see_link&amp;anchor=H2#H2\">",
"       \"Etiology, clinical features, and diagnosis of minimal change disease in adults\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other non-immunoglobulin factors derived from the serum of patients with FSGS are also able to induce increased glomerular permeability in experimental animals [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The identity of the putative permeability factor(s) in humans is not known. Currently available in vitro assays are crude and experimental, and correlations with clinical activity have been inconsistent. Although studied primarily in idiopathic FSGS, such factors have also been reported in other, non-immune disorders of glomerular permeability [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. A study has implicated cardiotrophin-like cytokine 1 (CLC1) as one possible factor in recurrent FSGS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism(s) by which non-immunoglobulin permeability factors act on the podocyte to cause such dramatic increases in glomerular permeability are unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/9\">",
"     9",
"    </a>",
"    ]. The ability of some antibodies specific for slit diaphragm proteins to mimic this effect suggests that alterations in slit diaphragm structure and function may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/17,19,20\">",
"     17,19,20",
"    </a>",
"    ]. Interference with podocyte attachment to GBM may also be a mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Complement membrane attack complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complement membrane attack complex, C5b-9, is another established mediator of noninflammatory immune injury. In idiopathic membranous nephropathy (MN), the development of subepithelial immune deposits of IgG (usually IgG4 subclass), C3, and C5b-9 induces large increases in glomerular protein permeability without significant histologic alterations (",
"    <a class=\"graphic graphic_picture graphicRef57841 graphicRef74698 graphicRef55226 graphicRef62937 graphicRef69348 \" href=\"UTD.htm?43/44/44746\">",
"     picture 1A-E",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/22-28\">",
"     22-28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=see_link\">",
"     \"Causes and diagnosis of membranous nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An understanding of the mechanisms that underlie MN has evolved largely from studies of the Heymann nephritis models of MN in rats, which is indistinguishable pathologically, immunopathologically, and functionally from its human counterpart [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/23,29\">",
"     23,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10647?source=see_link\">",
"     \"Overview and clinical assessment of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the Heymann nephritis models, subepithelial deposits develop as a consequence of IgG antibody binding in situ to antigenic structures located in the clathrin-coated pits of the podocyte, now referred to as megalin, or the Heymann nephritis antigenic complex (HNAC) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/30\">",
"     30",
"    </a>",
"    ]. As the immune aggregates are formed, and then capped and shed from the podocyte surface to form discrete subepithelial deposits, complement is activated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]; C3 and C5-C9 are usually constituents of the deposits [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/23,29,31\">",
"     23,29,31",
"    </a>",
"    ]. In the rat models, complement activation requires simultaneous inactivation of complement regulatory proteins expressed by the podocyte and occurs through the alternative complement pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/30,33,34\">",
"     30,33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10647?source=see_link\">",
"     \"Overview and clinical assessment of the complement system\"",
"    </a>",
"    .) Unlike the antigen-antibody complexes that are shed from the cell surface, C5b-9 inserts into the podocyte membrane and is then transported across the cell to be extruded into the urinary space resulting in elevated levels of C5b-9 in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/2,29,35,36\">",
"     2,29,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    C5b-9 is thought to be the principal mediator of altered glomerular barrier function in MN, because selective depletion or genetic absence of any terminal complement component greatly reduces the ability of antibodies to the HNAC to induce proteinuria in the intact animal, the isolated perfused kidney, and the isolated glomerulus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. A similar mechanism in humans is inferred from the virtual identity of the lesions in rat and man, the presence of C3 and C5b-9 in subepithelial deposits in both rat and man, and the selective increase in C5b-9 excretion in the urine in active MN [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/36\">",
"     36",
"    </a>",
"    ]. However, complement-independent models of membranous nephropathy have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms involved in the sublytic effects of C5b-9 on the podocyte that lead to proteinuria primarily involve the production of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. C5b-9 also increases the expression of transforming growth factor (TGF) beta-2 and TGF beta-3 and TGF receptors leading to overproduction of extracellular matrix that results in GBM thickening and \"spike\" formation (",
"    <a class=\"graphic graphic_picture graphicRef69629 \" href=\"UTD.htm?24/54/25445\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. C5b-9 attack also leads to podocyte apoptosis, detachment and excretion in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/40\">",
"     40",
"    </a>",
"    ], as well as DNA damage and alterations in cell cycle proteins that favor hypertrophy over proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Together, these changes contribute to eventual glomerular sclerosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=see_link\">",
"     \"Causes and diagnosis of membranous nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While studies of the role of C5b-9 in glomerular disease have focused primarily on the podocyte and membranous nephropathy, good evidence exists that similar C5b-9-mediated processes are also responsible for immune injury to mesangial cells (IgA nephropathy, SLE), endothelial cells (SLE, MPGN type I), and the tubulointerstitium in any condition with non-selective proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/2,41-43\">",
"     2,41-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INFLAMMATORY MECHANISMS OF GLOMERULAR INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A vigorous cellular response is generally observed in renal diseases in which immune deposits form in the GBM (anti-GBM antibody disease), on the inner surface of the capillary wall (subendothelial deposits in lupus nephritis and MPGN type I), or in the mesangium (IgA nephropathy, lupus). These deposits initiate multiple inflammatory processes, particularly complement activation, pro-coagulant activity, cytokine and growth factor release, and chemoattractant generation. However, severe inflammation can also occur in the absence of significant antibody deposition (eg, in ANCA-positive crescentic GN). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Neutrophils'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Unlike podocyte-derived substances resulting from subepithelial immune complex formation in MN, chemoattractants, complement activation products, and cytokines generated on the inner surface of the capillary wall directly access the vascular space, resulting in the infiltration of circulating inflammatory cells (neutrophils, platelets, lymphocytes, and macrophages) and upregulation of leukocyte adhesion molecules; resident glomerular cells also proliferate, particularly mesangial cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40261?source=see_link\">",
"     \"Pathogenesis of tissue injury in glomerulonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following section summarizes the roles of the major mediators and effector cells in inflammatory types of GN:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Complement and other humoral mediators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although understanding of the role of complement in both inflammatory and noninflammatory forms of glomerular injury has expanded dramatically, the generation of the chemotactic factor C5a is particularly important in antibody-induced glomerular inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/33,44-46\">",
"     33,44-46",
"    </a>",
"    ]. The importance of complement activation, complement regulatory proteins, chemokines, and cytokines can be illustrated by the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/24,25,33,44-51\">",
"     24,25,33,44-51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immune complex mediated nephritis is significantly ameliorated in transgenic mice massively expressing a complement inhibitor in plasma and in mice in which the genes for the complement components C3 and C4 have been deleted [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/24,48\">",
"       24,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Immune complex mediated nephritis and the associated inflammatory cell infiltration is significantly reduced by the administration of an antibody directed against macrophage migration inhibitory factor [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/49,52\">",
"       49,52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anti-glomerular basement membrane nephritis is made worse by the absence of complement regulatory proteins [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Deficiency or antagonism of chemokines (such as monocyte chemoattractant protein [MCP]-1 and RANTES)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chemokine receptors (including CCR2 and CCR5) helps prevent glomerulonephritis in animal models [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/53-57\">",
"       53-57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abrogation of signaling pathways that result in upregulation of MCP-1 and TNF alpha is associated with decreased proteinuria and less tubulointerstitial injury in a murine model of anti-GBM disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neutrophils",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophils are present in the early biopsies of patients with post-streptococcal glomerulonephritis (GN), membranoproliferative GN, Henoch-Sch&ouml;nlein purpura (HSP, also termed IgA vasculitis [IgAV]), systemic lupus erythematosus (SLE), and some forms of rapidly progressive glomerulonephritis (RPGN) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=see_link\">",
"     \"Poststreptococcal glomerulonephritis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neutrophil localization in glomerular capillaries is dependent upon the generation of chemotactic factors within and around an inflammatory focus; the most prominent chemoattractants in glomerular disease are C5a (derived from activation of complement) and several chemokines, such as interleukin-8, which can be bound to endothelial cells via heparan sulfate proteoglycans [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/25,47,61-64\">",
"     25,47,61-64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once attracted, neutrophil localization involves the interaction between adhesion molecules expressed on glomerular endothelial cells, such as selectins, integrins",
"    <span class=\"nowrap\">",
"     (CD11/CD18),",
"    </span>",
"    and Ig-like molecules (ICAM-1), and their corresponding ligands on the neutrophil [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/25,47,63,65\">",
"     25,47,63,65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At the site of immune deposit formation, neutrophils phagocytose the immune complex aggregates, become activated and undergo a respiratory burst that generates reactive oxygen species [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/66\">",
"     66",
"    </a>",
"    ]. Several studies have shown",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    to be the principal neutrophil-derived oxidant that mediates glomerular injury. Hydrogen peroxide is nephritogenic because of interactions with another neutrophil-derived cationic enzyme myeloperoxidase (MPO) (which also localizes in glomeruli because of charge) and a halide to form hypohalous acids, which halogenate the glomerular capillary wall [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/63,66\">",
"     63,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neutrophils also store cationic serine proteases, such as elastase and cathepsin G, within azurophilic granules. The activation of neutrophils within glomeruli causes the extracellular release of these proteins, thereby resulting in the degradation of elements of the glomerular capillary wall. MPO and PR3, both cationic proteases localized in the primary granules of neutrophils, are also involved in the pathogenesis of ANCA-positive crescentic glomerulonephritis; they are localized in primary granules and displayed on the cell surface in response to certain cytokines. There they are accessible to ANCA antibody and become activated, resulting in capillary localization and release of oxidants and proteases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=see_link\">",
"     \"Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides\"",
"    </a>",
"    .) Evidence in animal models suggests that ANCA-neutrophil interaction also induces release of a complement-activating factor that contributes to the mediation of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of leukocyte-mediated immune glomerular injury is supported by many observations in animal models, including beneficial effects of both neutrophil depletion and interference with adhesion molecule function, and studies utilizing animals genetically deficient in neutrophil enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/47,67\">",
"     47,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Macrophages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrophages are also prominent constituents of several glomerular lesions, particularly ones that exhibit crescent formation such as RPGN, SLE, and cryoglobulinemic nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/26,70-72\">",
"     26,70-72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/27/43448?source=see_link\">",
"     \"Mechanisms of glomerular crescent formation\"",
"    </a>",
"    .) The importance of",
"    <span class=\"nowrap\">",
"     monocytes/macrophages",
"    </span>",
"    in mediating glomerular injury is well-documented by studies, such as macrophage depletion and inhibition of MIF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/18,26,49,51,52,72\">",
"     18,26,49,51,52,72",
"    </a>",
"    ]. The protective effect of absent granulocyte macrophage colony-stimulating factor is illustrated in GM-CSF",
"    <span class=\"nowrap\">",
"     -/-",
"    </span>",
"    mice, which exhibited less infiltration of monocytes compared to wild type and were protected from crescentic glomerular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Macrophages localize to glomeruli via interactions with both deposited immunoglobulins (through Fc receptors) and several chemokines, such as macrophage chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1-alpha (MIP-1alpha) and RANTES [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/26,73,74\">",
"     26,73,74",
"    </a>",
"    ]. Unlike neutrophils, macrophages are also readily recruited by lymphocyte-derived molecules, such as macrophage inhibitory factor (MIF), that result from the interaction between specifically sensitized T-cells and intraglomerular antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/49\">",
"     49",
"    </a>",
"    ]. In addition, monocytes also localize through interaction with leukocyte adhesion molecules, such as ICAM-1 and VCAM-1, as well as osteopontin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/26,72,75\">",
"     26,72,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, macrophages may serve as effector cells in both humoral and cell-mediated forms of immune injury and are presumed to be the principal effector cells in inflammatory glomerular lesions induced by sensitized T-cells in the absence of antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/52,60,72\">",
"     52,60,72",
"    </a>",
"    ]. As with neutrophils, macrophages may generate oxidants and proteases. However, unlike neutrophils, they release tissue factor (which initiates fibrin deposition and crescent formation) and TGF beta (which contributes to the synthesis of extracellular matrix and eventual development of sclerosis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/27/43448?source=see_link\">",
"     \"Mechanisms of glomerular crescent formation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cells are rarely conspicuous in glomerular lesions, but can be detected, particularly in diseases primarily mediated by macrophages such as crescentic GN [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/26,60,70,72\">",
"     26,60,70,72",
"    </a>",
"    ]. Although there is experimental evidence that glomerular injury can be induced by systemic T-cells in the absence of antibody deposition, little evidence exists that glomerular T-cells alone are nephritogenic, with the exception of permeability factors (discussed above) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/76\">",
"     76",
"    </a>",
"    ]. Instead, T-cell mediated injury occurs primarily via the release of chemokines and recruitment of macrophages, which subsequently function as effector cells. In addition, T cells may be the source of permeability factors that contribute to noninflammatory glomerular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/12,72\">",
"     12,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelets are prominent in several glomerular lesions, usually ones that involve intraglomerular thrombosis such as SLE, anti-phospholipid antibody syndromes, and thrombotic microangiopathies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1146?source=see_link\">",
"     \"Platelet biology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .) In addition to their role in thrombotic processes involving endothelial cell injury, platelets also release a number of products that participate in and augment glomerular injury, more broadly including vasoactive, mitogenic, and chemotactic substances [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/77\">",
"     77",
"    </a>",
"    ]. For example, platelet-derived factors such as PAF and platelet factor 4 enhance glomerular permeability to proteins and immune complex deposition, and PDGF and TGF contribute to mesangial cell proliferation and sclerosis, respectively. Platelets have also been shown to contribute to neutrophil-mediated glomerular injury through non-chemotactic mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Injury induced by activation and/or proliferation of resident glomerular cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike the noninflammatory processes involved in diseases in which the podocyte is targeted (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9304?source=see_link\">",
"     \"Biology of glomerular podocytes\"",
"    </a>",
"    ), disorders in which glomerular endothelial and mesangial cells are principally involved exhibit a more dramatic response to immune injury. This response is usually characterized by cell proliferation and phenotype change, as well as readily visible structural changes in the renal biopsy.",
"   </p>",
"   <p>",
"    Glomerular endothelial cells (GEN) appear to be the principal targets of injury in some diseases, such as hemolytic uremic syndrome and vasculitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18231?source=see_link\">",
"     \"Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GEN injury can induce proliferation, phenotype change (expression of adhesion molecules), release of vasoactive agents (endothelin, nitric oxide), and conversion to a prothrombotic state [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/27,78\">",
"     27,78",
"    </a>",
"    ]. GEN injury is characterized by proliferation, apoptosis, detachment, and (particularly) thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Considerably more attention has been directed to the role of the glomerular mesangial cell in those diseases in which the mesangium is involved; this most commonly occurs with immune deposit formation in the mesangium, a finding observed with IgA nephropathy, HSP (IgAV), SLE, and other disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/48/20233?source=see_link\">",
"     \"Pathogenesis of IgA nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=see_link\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because glomerular mesangial cells can be readily cultured and studied in vitro, a long list of mediators which can activate mesangial cells has been established [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/28,32,46,79-83\">",
"     28,32,46,79-83",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cytokines, such as interleukin-1, tumor necrosis factor, TWEAK, and others [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/84\">",
"       84",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Growth factors, such as platelet derived growth factor (PDGF), TGF beta, connective tissue growth factor, basic fibroblast growth factor, and VEGF [",
"      <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/85\">",
"       85",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      C5b-9",
"     </li>",
"     <li>",
"      Immune complexes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mesangial response to injury is characterized by alterations in cell cycle proteins that favor cell proliferation, phenotype change (to an actin positive myofibroblast), extracellular matrix production, and apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/79\">",
"     79",
"    </a>",
"    ]. Many of these effects involve agonist interaction with specific receptors on the mesangial cell, including receptors for IgA, toll-like receptors, and transferrin receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/46\">",
"     46",
"    </a>",
"    ]. PDGF appears to be the principal mediator of mesangial cell migration and proliferation in glomerular disease, an effect possibly magnified in hypoxic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/32,79,80,85\">",
"     32,79,80,85",
"    </a>",
"    ]. Receptors for PDGF are also upregulated. Further support for a role for PDGF is provided by a study that demonstrated prevention of renal scarring by antagonism of PDGF in an animal model of glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mesangial cell proliferation is associated with the increased expression of cyclin-dependent kinases and reduced expression of cyclin kinase inhibitors, such as P21 and P27 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/81\">",
"     81",
"    </a>",
"    ]. Mesangial cell proliferation is an essential precursor to subsequent mesangial matrix expansion and sclerosis, due primarily to the actions of TGF and CTGF. Increased prostanoid synthesis, possibly modulated by TGF, may also have a role in this process [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Therapeutic interventions, which target mesangial cell proliferation or matrix production, can therefore greatly ameliorate both acute and chronic forms of glomerular injury in those disorders in which glomerular cell proliferation is prominent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/30/18921/abstract/32,79,88\">",
"     32,79,88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glomerular immune injury is mediated by the actions of both the innate and adaptive immune systems. Glomerular lesions may be inflammatory or noninflammatory. With inflammatory lesions, glomerular hypercellularity is due to infiltrating hematopoietic cells (such as neutrophils and macrophages)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      proliferating glomerular cells. These effector cells induce thrombosis, necrosis, and crescent formation, which may result in rapidly progressive renal insufficiency and nephritis. With noninflammatory lesions resulting from immune injury (ie, podocytopathies), the podocyte is the major effecter cell. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Podocytopathies, such as minimal change nephrotic",
"      <span class=\"nowrap\">",
"       syndrome/focal",
"      </span>",
"      segmental glomerulosclerosis",
"      <span class=\"nowrap\">",
"       (MCNS/FSGS)",
"      </span>",
"      and membranous nephropathy (MN), are associated with a functional change of the glomerulus (usually an increase in protein permeability), but without light microscopic evidence of damage. This results in nephrotic range proteinuria and may lead to glomerular sclerosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Noninflammatory mechanisms of immune glomerular injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immune mediators that induce podocyte dysfunction sufficiently to result in nephrotic-range proteinuria without inflammation include T cell-derived factors, vasoactive agents, C5b-9, and cytokines like IL13 and cardiotropin-like cytokine 1 (CLC1). With",
"      <span class=\"nowrap\">",
"       MCNS/FSGS,",
"      </span>",
"      a non-immunoglobulin circulating permeability factor is postulated, although the identity of this factor is unknown; one study has implicated cardiotrophin-like cytokine 1 (CLC1) as one possible factor in recurrent FSGS. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenic agents in podocytopathies of immune origin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Glomerular permeability factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanisms by which non-immunoglobulin permeability factors increase glomerular permeability are unknown. Alterations in slit diaphragm structure and function or interference with podocyte attachment to GBM may be involved. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Glomerular permeability factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The complement membrane attack complex, C5b-9, is another established mediator of noninflammatory immune injury. In MN, subepithelial immune deposits of IgG, C3, and C5b-9 increase glomerular protein permeability without significant histologic alterations. Similar C5b-9-mediated processes are also responsible for immune injury to mesangial cells (IgA nephropathy, SLE), endothelial cells (SLE, MPGN type I), and the tubulointerstitium in any condition with non-selective proteinuria. Complement-independent models of membranous nephropathy have also been reported. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Complement membrane attack complex'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A vigorous cellular response is observed in renal diseases characterized by immune deposits in the glomerular basement membrane (GBM) (anti-GBM antibody disease), the inner surface of the capillary wall (subendothelial deposits in lupus nephritis and MPGN type I), or the mesangium (IgA nephropathy, lupus). Immune deposits initiate inflammatory processes, including complement activation, cytokine and growth factor release, pro-coagulant activity, and chemoattractant generation. Severe inflammation can also occur in the absence of significant antibody deposition (eg, in ANCA-positive crescentic GN). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Inflammatory mechanisms of glomerular injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major effector cells in inflammatory types of glomerulonephritis include complement and other humoral mediators; neutrophils; macrophage; T cells; and platelets. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Complement and other humoral mediators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unlike the noninflammatory processes involved in diseases that target the podocyte, disorders that target endothelial and mesangial cells exhibit a dramatic response to injury characterized by cell proliferation and phenotype change, as well as visible structural changes observed on histology. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Injury induced by activation and/or proliferation of resident glomerular cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glomerular endothelial cells (GEN) are targets of injury in hemolytic uremic syndrome and vasculitis. GEN injury is characterized by proliferation, apoptosis, detachment, and (particularly) thrombosis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Injury induced by activation and/or proliferation of resident glomerular cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The glomerular mesangial cell is targeted in IgA nephropathy, Henoch-Sch&ouml;nlein purpura (HSP, also termed IgA vasculitis [IgAV]), SLE, and other disorders. Mediators that activate mesangial cells include cytokines, such as interleukin-1, tumor necrosis factor, TWEAK, and others; growth factors, such as platelet derived growth factor (PDGF), TGF beta, connective tissue growth factor, basic fibroblast growth factor, and VEGF; C5b-9; and immune complexes. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Injury induced by activation and/or proliferation of resident glomerular cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mesangial response to injury is characterized by alterations in cell cycle proteins that favor cell proliferation, phenotype change (to an actin positive myofibroblast), extracellular matrix production, and apoptosis. Mesangial cell proliferation is associated with the increased expression of cyclin-dependent kinases and reduced expression of cyclin kinase inhibitors, such as P21 and P27. Mesangial cell proliferation is a precursor to matrix expansion and sclerosis, due to the actions of TGF and CTGF, and possibly increased prostanoid synthesis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Injury induced by activation and/or proliferation of resident glomerular cells'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/1\">",
"      Nangaku M, Couser WG. Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol 2005; 9:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/2\">",
"      Chadban SJ, Atkins RC. Glomerulonephritis. Lancet 2005; 365:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/3\">",
"      van den Berg JG, Weening JJ. Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome. Clin Sci (Lond) 2004; 107:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/4\">",
"      Tipping PG. Are podocytes passive or provocative in proteinuric glomerular pathology? J Am Soc Nephrol 2008; 19:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/5\">",
"      Mathieson PW. Minimal change nephropathy and focal segmental glomerulosclerosis. Semin Immunopathol 2007; 29:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/6\">",
"      Savin, VJ, Sharma, M, McCarthy, ET, et al. Cardiotrophin like cytokine 1:Candidate for the focal glomerular sclerosis permeability factor. J Amer Soc Nephrol 2008; 19:59a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/7\">",
"      Ali AA, Wilson E, Moorhead JF, et al. Minimal-change glomerular nephritis. Normal kidneys in an abnormal environment? Transplantation 1994; 58:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/8\">",
"      Hoyer JR, Vernier RL, Najarian JS, et al. Recurrence of idiopathic nephrotic syndrome after renal transplantation. Lancet 1972; 2:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/9\">",
"      McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010; 5:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/10\">",
"      Cattran D, Neogi T, Sharma R, et al. Serial estimates of serum permeability activity and clinical correlates in patients with native kidney focal segmental glomerulosclerosis. J Am Soc Nephrol 2003; 14:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/11\">",
"      Ghiggeri GM, Artero M, Carraro M, Perfumo F. Permeability plasma factors in nephrotic syndrome: more than one factor, more than one inhibitor. Nephrol Dial Transplant 2001; 16:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/12\">",
"      Koyama A, Fujisaki M, Kobayashi M, et al. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 1991; 40:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/13\">",
"      Sellier-Leclerc AL, Duval A, Riveron S, et al. A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells. J Am Soc Nephrol 2007; 18:2732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/14\">",
"      Yap HK, Cheung W, Murugasu B, et al. Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 1999; 10:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/15\">",
"      Lai KW, Wei CL, Tan LK, et al. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J Am Soc Nephrol 2007; 18:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/16\">",
"      Dantal J, Bigot E, Bogers W, et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994; 330:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/17\">",
"      Koop K, Eikmans M, Baelde HJ, et al. Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol 2003; 14:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/18\">",
"      Glassock RJ. Circulating permeability factors in the nephrotic syndrome: a fresh look at an old problem. J Am Soc Nephrol 2003; 14:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/19\">",
"      Liu G, Kaw B, Kurfis J, et al. Neph1 and nephrin interaction in the slit diaphragm is an important determinant of glomerular permeability. J Clin Invest 2003; 112:209.",
"     </a>",
"    </li>",
"    <li>",
"     Salant, DJ, Natori, Y, Kawashi, H. Glomerular injury due to antibody alone. In: Immunologic renal diseases, 2nd ed, Neilson, E, Couser, WG (Eds), Lippincott-Williams and Wilkins, Philadelphia 2001. p.347.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/21\">",
"      Kriz W, LeHir M. Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int 2005; 67:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/22\">",
"      Nangaku M, Shankland SJ, Couser WG. Cellular response to injury in membranous nephropathy. J Am Soc Nephrol 2005; 16:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/23\">",
"      Mundel P, Shankland SJ. Podocyte biology and response to injury. J Am Soc Nephrol 2002; 13:3005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/24\">",
"      Quigg RJ. Role of complement and complement regulatory proteins in glomerulonephritis. Springer Semin Immunopathol 2003; 24:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/25\">",
"      Segerer S, Nelson PJ, Schl&ouml;ndorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 2000; 11:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/26\">",
"      Nikolic-Paterson DJ, Atkins RC. The role of macrophages in glomerulonephritis. Nephrol Dial Transplant 2001; 16 Suppl 5:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/27\">",
"      Kang DH, Kanellis J, Hugo C, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002; 13:806.",
"     </a>",
"    </li>",
"    <li>",
"     Rupprecht, HD, Schocklmann, HO, Sterzel, RB. Glomerular mesangial cells. In: Immunologic renal diseases, Neilson, EG, Couser, WG (Eds), Lippincott-Raven, Philadelphia 2001. p.657.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/29\">",
"      Couser WG. Membranous nephropathy: a long road but well traveled. J Am Soc Nephrol 2005; 16:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/30\">",
"      Ronco P, Debiec H. Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization. J Am Soc Nephrol 2005; 16:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/31\">",
"      Falk RJ, Dalmasso AP, Kim Y, et al. Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest 1983; 72:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/32\">",
"      Ostendorf T, Kunter U, van Roeyen C, et al. The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-beta system. J Am Soc Nephrol 2002; 13:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/33\">",
"      Puri TS, Quigg RJ. The many effects of complement C3- and C5-binding proteins in renal injury. Semin Nephrol 2007; 27:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/34\">",
"      Cunningham PN, Quigg RJ. Contrasting roles of complement activation and its regulation in membranous nephropathy. J Am Soc Nephrol 2005; 16:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/35\">",
"      Kerjaschki D, Schulze M, Binder S, et al. Transcellular transport and membrane insertion of the C5b-9 membrane attack complex of complement by glomerular epithelial cells in experimental membranous nephropathy. J Immunol 1989; 143:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/36\">",
"      Schulze M, Donadio JV Jr, Pruchno CJ, et al. Elevated urinary excretion of the C5b-9 complex in membranous nephropathy. Kidney Int 1991; 40:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/37\">",
"      Couser WG. Pathogenesis of glomerular damage in glomerulonephritis. Nephrol Dial Transplant 1998; 13 Suppl 1:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/38\">",
"      Saran AM, Yuan H, Takeuchi E, et al. Complement mediates nephrin redistribution and actin dissociation in experimental membranous nephropathy. Kidney Int 2003; 64:2072.",
"     </a>",
"    </li>",
"    <li>",
"     Spicer, ST, Tran, GT, Killingsworth, MC, et al. Induction of passive Heymann nephritis in complement component 6-deficient PVG rats.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/40\">",
"      Zachem CR, Alpers CE, Way W, et al. A role for P-selectin in neutrophil and platelet infiltration in immune complex glomerulonephritis. J Am Soc Nephrol 1997; 8:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/41\">",
"      Hsu SI, Couser WG. Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: a therapeutic role for complement inhibitors? J Am Soc Nephrol 2003; 14:S186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/42\">",
"      Brandt J, Pippin J, Schulze M, et al. Role of the complement membrane attack complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis. Kidney Int 1996; 49:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/43\">",
"      Nangaku M, Alpers CE, Pippin J, et al. Renal microvascular injury induced by antibody to glomerular endothelial cells is mediated by C5b-9. Kidney Int 1997; 52:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/44\">",
"      Turnberg D, Cook HT. Complement and glomerulonephritis: new insights. Curr Opin Nephrol Hypertens 2005; 14:223.",
"     </a>",
"    </li>",
"    <li>",
"     Berger, SP, Daha, MR. Complement in glomerular injury.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/46\">",
"      Sacks S, Zhou W. New boundaries for complement in renal disease. J Am Soc Nephrol 2008; 19:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/47\">",
"      De Vriese AS, Endlich K, Elger M, et al. The role of selectins in glomerular leukocyte recruitment in rat anti-glomerular basement membrane glomerulonephritis. J Am Soc Nephrol 1999; 10:2510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/48\">",
"      H&eacute;bert MJ, Takano T, Papayianni A, et al. Acute nephrotoxic serum nephritis in complement knockout mice: relative roles of the classical and alternate pathways in neutrophil recruitment and proteinuria. Nephrol Dial Transplant 1998; 13:2799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/49\">",
"      Lan HY, Bacher M, Yang N, et al. The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med 1997; 185:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/50\">",
"      Segerer S, Henger A, Schmid H, et al. Expression of the chemokine receptor CXCR1 in human glomerular diseases. Kidney Int 2006; 69:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/51\">",
"      Tipping PG, Holdsworth SR. Cytokines in glomerulonephritis. Semin Nephrol 2007; 27:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/52\">",
"      Yang N, Nikolic-Paterson DJ, Ng YY, et al. Reversal of established rat crescentic glomerulonephritis by blockade of macrophage migration inhibitory factor (MIF): potential role of MIF in regulating glucocorticoid production. Mol Med 1998; 4:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/53\">",
"      Tesch GH, Maifert S, Schwarting A, et al. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J Exp Med 1999; 190:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/54\">",
"      Hasegawa H, Kohno M, Sasaki M, et al. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum 2003; 48:2555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/55\">",
"      Han GD, Suzuki K, Koike H, et al. IFN-inducible protein-10 plays a pivotal role in maintaining slit-diaphragm function by regulating podocyte cell-cycle balance. J Am Soc Nephrol 2006; 17:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/56\">",
"      Kulkarni O, Pawar RD, Purschke W, et al. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol 2007; 18:2350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/57\">",
"      Stasikowska O, Wagrowska-Danilewicz M. Chemokines and chemokine receptors in glomerulonephritis and renal allograft rejection. Med Sci Monit 2007; 13:RA31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/58\">",
"      Flanc RS, Ma FY, Tesch GH, et al. A pathogenic role for JNK signaling in experimental anti-GBM glomerulonephritis. Kidney Int 2007; 72:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/59\">",
"      Ishida-Okawara A, Ito-Ihara T, Muso E, et al. Neutrophil contribution to the crescentic glomerulonephritis in SCG/Kj mice. Nephrol Dial Transplant 2004; 19:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/60\">",
"      Tipping PG, Holdsworth SR. T cells in glomerulonephritis. Springer Semin Immunopathol 2003; 24:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/61\">",
"      Kitching AR, Ru Huang X, Turner AL, et al. The requirement for granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in leukocyte-mediated immune glomerular injury. J Am Soc Nephrol 2002; 13:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/62\">",
"      Rops AL, van der Vlag J, Lensen JF, et al. Heparan sulfate proteoglycans in glomerular inflammation. Kidney Int 2004; 65:768.",
"     </a>",
"    </li>",
"    <li>",
"     Johnson, RJ, Klebanoff, SJ, Couser, WG. Neutrophils (Chapter 25). In: Immunologic Renal Diseases. Neilson, EG, Couser, WG, (Eds), Lippincott-Wilkins, Philadelphia 2001 p.579.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/64\">",
"      Segerer S, Schl&ouml;ndorff D. Role of chemokines for the localization of leukocyte subsets in the kidney. Semin Nephrol 2007; 27:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/65\">",
"      Ito I, Yuzawa Y, Mizuno M, et al. Effects of a new synthetic selectin blocker in an acute rat thrombotic glomerulonephritis. Am J Kidney Dis 2001; 38:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/66\">",
"      Johnson RJ, Couser WG, Chi EY, et al. New mechanism for glomerular injury. Myeloperoxidase-hydrogen peroxide-halide system. J Clin Invest 1987; 79:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/67\">",
"      Xiao H, Heeringa P, Liu Z, et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol 2005; 167:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/68\">",
"      Huugen D, van Esch A, Xiao H, et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int 2007; 71:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/69\">",
"      Jennette JC, Falk RJ. New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies. Curr Opin Rheumatol 2008; 20:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/70\">",
"      Hooke DH, Gee DC, Atkins RC. Leukocyte analysis using monoclonal antibodies in human glomerulonephritis. Kidney Int 1987; 31:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/71\">",
"      Rastaldi MP, Ferrario F, Crippa A, et al. Glomerular monocyte-macrophage features in ANCA-positive renal vasculitis and cryoglobulinemic nephritis. J Am Soc Nephrol 2000; 11:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/72\">",
"      Kurts C, Heymann F, Lukacs-Kornek V, et al. Role of T cells and dendritic cells in glomerular immunopathology. Semin Immunopathol 2007; 29:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/73\">",
"      Timoshanko JR, Kitching AR, Semple TJ, et al. Granulocyte macrophage colony-stimulating factor expression by both renal parenchymal and immune cells mediates murine crescentic glomerulonephritis. J Am Soc Nephrol 2005; 16:2646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/74\">",
"      Shimizu H, Maruyama S, Yuzawa Y, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria. J Am Soc Nephrol 2003; 14:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/75\">",
"      Okada H, Moriwaki K, Konishi K, et al. Tubular osteopontin expression in human glomerulonephritis and renal vasculitis. Am J Kidney Dis 2000; 36:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/76\">",
"      Rennke HG, Klein PS, Sandstrom DJ, Mendrick DL. Cell-mediated immune injury in the kidney: acute nephritis induced in the rat by azobenzenearsonate. Kidney Int 1994; 45:1044.",
"     </a>",
"    </li>",
"    <li>",
"     Barnes, JL. Platelets. In: Immunologic Renal Diseases, 2nd ed, Neilson, EG, Couser, WG (Eds), Lippincott Williams and Wilkins, Philadelphia 2001. p 593.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/78\">",
"      Segal MS, Baylis C, Johnson RJ. Endothelial health and diversity in the kidney. J Am Soc Nephrol 2006; 17:323.",
"     </a>",
"    </li>",
"    <li>",
"     Floege, J, Ostendorf, T, Wolf, G. Growth factors and cytokines. In: Immunologic renal diseases, Neilson, EG, Couser, WG (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2001. p.415.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/80\">",
"      Eng E, Holgren C, Hubchak S, et al. Hypoxia regulates PDGF-B interactions between glomerular capillary endothelial and mesangial cells. Kidney Int 2005; 68:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/81\">",
"      Griffin SV, Pichler R, Wada T, et al. The role of cell cycle proteins in Glomerular disease. Semin Nephrol 2003; 23:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/82\">",
"      Ostendorf T, Rong S, Boor P, et al. Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 2006; 17:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/83\">",
"      Tan Y, Wang B, Keum JS, Jaffa AA. Mechanisms through which bradykinin promotes glomerular injury in diabetes. Am J Physiol Renal Physiol 2005; 288:F483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/84\">",
"      Sanz AB, Moreno JA, Sanchez-Nino MD, et al. TWEAKing renal injury. Front Biosci 2008; 13:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/85\">",
"      Floege J, Eitner F, Alpers CE. A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 2008; 19:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/86\">",
"      Gon&ccedil;alves AR, Fujihara CK, Mattar AL, et al. Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory. Am J Physiol Renal Physiol 2004; 286:F945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/87\">",
"      Harding P, Balasubramanian L, Swegan J, et al. Transforming growth factor beta regulates cyclooxygenase-2 in glomerular mesangial cells. Kidney Int 2006; 69:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/30/18921/abstract/88\">",
"      Suzuki S, Gejyo F, Kuroda T, et al. Effects of a novel elastase inhibitor, ONO-5046, on nephrotoxic serum nephritis in rats. Kidney Int 1998; 53:1201.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3068 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.65.66-BC5B390E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_30_18921=[""].join("\n");
var outline_f18_30_18921=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NONINFLAMMATORY MECHANISMS OF IMMUNE GLOMERULAR INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENIC AGENTS IN PODOCYTOPATHIES OF IMMUNE ORIGIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Glomerular permeability factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Complement membrane attack complex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INFLAMMATORY MECHANISMS OF GLOMERULAR INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Complement and other humoral mediators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neutrophils",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Macrophages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Platelets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Injury induced by activation and/or proliferation of resident glomerular cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3068\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3068|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/47/5887\" title=\"figure 1\">",
"      Mechanisms of glomerular damage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3068|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/16/16649\" title=\"picture 1A\">",
"      Membranous Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/42/28321\" title=\"picture 1B\">",
"      Membranous IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/46/39656\" title=\"picture 1C\">",
"      Membranous EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/5/32856\" title=\"picture 1D\">",
"      Membranous EM II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/39/39543\" title=\"picture 1E\">",
"      SLE Membranous EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/54/25445\" title=\"picture 2\">",
"      Membranous Silver",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9304?source=related_link\">",
"      Biology of glomerular podocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=related_link\">",
"      Causes and diagnosis of membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=related_link\">",
"      Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34601?source=related_link\">",
"      Etiology, clinical features, and diagnosis of minimal change disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33722?source=related_link\">",
"      Focal segmental glomerulosclerosis in the transplanted kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/27/43448?source=related_link\">",
"      Mechanisms of glomerular crescent formation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10647?source=related_link\">",
"      Overview and clinical assessment of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18231?source=related_link\">",
"      Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/48/20233?source=related_link\">",
"      Pathogenesis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=related_link\">",
"      Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40261?source=related_link\">",
"      Pathogenesis of tissue injury in glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1146?source=related_link\">",
"      Platelet biology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=related_link\">",
"      Poststreptococcal glomerulonephritis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_30_18922="Geography PPD reactors USA";
var content_f18_30_18922=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Geographic distribution of PPD skin test reactors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 391px; height: 578px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Geographic variation in the frequency of reactors to PPD-S (top) and to PPD-B 9 (bottom).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Edwards, et al, Am Rev Respir Dis 1969; 99(Suppl):1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_30_18922=[""].join("\n");
var outline_f18_30_18922=null;
var title_f18_30_18923="Histology endometrial cancer";
var content_f18_30_18923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histologic subtypes of endometrial carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Endometrioid adenocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Variant with squamous differentiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Villoglandular variant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Secretory variant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ciliated cell variant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serous adenocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clear cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mixed adenocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mucinous adenocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Squamous cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transitional cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Undifferentiated carcinoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tavasso&eacute;li FA, Devilee P. Tumours of the Breast and Female Genital Organs, WHO/IARC Classification of Tumours, IARC Press-WHO, France 2003.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_30_18923=[""].join("\n");
var outline_f18_30_18923=null;
var title_f18_30_18924="Mifepristone early fetal demise";
var content_f18_30_18924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F65083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F65083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medical management of early fetal demise with Mifepristone",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Number of women studied",
"       </td>",
"       <td class=\"subtitle1\">",
"        Regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Efficacy, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        60",
"       </td>",
"       <td>",
"        Mif 600 mg",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        93",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        El-Refaey et al, 1992",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Miso 400 mcg, 200 mcg, 2 hours apart (O)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        Mif 600 mg",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        Lelaidier et al, 1993",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        185",
"       </td>",
"       <td>",
"        Mif 200 mg. After 36-48 hours, 3 sequential doses of",
"Miso (O)",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        Hughes et al, 1996",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        Mif 400 mg. After 36 hours, Miso 400 mcg (O)",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        Nielsen et al, 1997",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        220",
"       </td>",
"       <td>",
"        Mif 200 mg. After 36-48 hours, Miso 800 mcg (V), 200",
"mcg, 400 mcg (V/O) at 3 hour intervals",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        Wagaarachchi et al, 2001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        Mif 200 mg (O). After 48 hours, Miso 800 mcg (V)",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        Schaff et al, 2001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        Mif 200 mg (O). After 48 hours, Miso 800 mcg (S), 400",
"mcg (S), 400 mcg (S) at 3 hour intervals",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        Wagaarachchi et al, 2002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        Mif 600 mg (O). After 48 hours, Miso 400 mcg (V) and",
"200 mcg (V) at 2 hourly intervals.",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        Gronlund et al, 2002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        Miso 400 mcg (V)",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        Gronlund et al, 2002",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Mif: Mifepristone; Miso: Misoprostol; O: oral; V: vaginal; S: sublingual.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_30_18924=[""].join("\n");
var outline_f18_30_18924=null;
var title_f18_30_18925="Ddx of aseptic meningitis";
var content_f18_30_18925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of aseptic meningitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common",
"       </td>",
"       <td class=\"subtitle1\">",
"        Uncommon",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viral",
"       </td>",
"       <td>",
"        <p>",
"         Echoviruses",
"        </p>",
"        <p>",
"         Coxsackieviruses types A and B",
"        </p>",
"        <p>",
"         Herpes simplex type 2",
"        </p>",
"        <p>",
"         Human immunodeficiency virus",
"        </p>",
"        <p>",
"         Lymphocytic choriomeningitis virus",
"        </p>",
"        <p>",
"         Arboviruses",
"        </p>",
"        <p>",
"         Mumps",
"        </p>",
"        <p>",
"         Poliovirus",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Cytomegalovirus",
"        </p>",
"        <p>",
"         Epstein Barr virus",
"        </p>",
"        <p>",
"         Varicella zoster virus",
"        </p>",
"        <p>",
"         Herpes simplex type I",
"        </p>",
"        <p>",
"         Adenovirus",
"        </p>",
"        <p>",
"         Measles",
"        </p>",
"        <p>",
"         Rubella",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Rotavirus",
"        </p>",
"        <p>",
"         Encephalomyocarditis virus",
"        </p>",
"        <p>",
"         Vaccinia",
"        </p>",
"        <p>",
"         Influenza A and B",
"        </p>",
"        <p>",
"         Parainfluenza",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacterial",
"       </td>",
"       <td>",
"        <p>",
"         Parameningeal bacterial infection (epidural, subdural abscess)",
"        </p>",
"        <p>",
"         Partially treated bacterial meningitis",
"        </p>",
"        <p>",
"         Leptospira spp.",
"        </p>",
"        <p>",
"         Borrelia burgdorferi (Lyme disease)",
"        </p>",
"        <p>",
"         Mycobacterium tuberculosis",
"        </p>",
"        <p>",
"         Bacterial endocarditis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Treponema pallidum (syphilis)",
"        </p>",
"        <p>",
"         Mycoplasma pneumoniae",
"        </p>",
"        <p>",
"         Rickettsia spp.",
"        </p>",
"        <p>",
"         Ehrlichia spp.",
"        </p>",
"        <p>",
"         Brucella spp.",
"        </p>",
"        <p>",
"         Chlamydia spp.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Borrelia recurrentis (relapsing fever)",
"        </p>",
"        <p>",
"         Spirillum minor (rat bite fever)",
"        </p>",
"        <p>",
"         Listeria monocytogenes",
"        </p>",
"        <p>",
"         Mycoplasma hominis",
"        </p>",
"        <p>",
"         Nocardia spp.",
"        </p>",
"        <p>",
"         Actinomyces spp.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fungal",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Cryptococcus neoformans",
"        </p>",
"        <p>",
"         Coccidioides immitis",
"        </p>",
"        <p>",
"         Histoplasma capsulatum",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Candida spp.",
"        </p>",
"        <p>",
"         Aspergillus spp.",
"        </p>",
"        <p>",
"         Blastomyces dermatitidis",
"        </p>",
"        <p>",
"         Sporothrix schenckii",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parasitic",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Angiostrongylus cantonensis",
"        </p>",
"        <p>",
"         Toxoplasma gondii",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Taenia solium (cysticercosis)",
"        </p>",
"        <p>",
"         Trichenella spiralis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug",
"       </td>",
"       <td>",
"        lbuprofen",
"       </td>",
"       <td>",
"        <p>",
"         Trimethoprim-sulfamethoxazole",
"        </p>",
"        <p>",
"         Other NSAIDs",
"        </p>",
"        <p>",
"         Pyridium (phenazopyridine)",
"        </p>",
"        <p>",
"         anti-CD3 monoclonal antibody",
"        </p>",
"        <p>",
"         Azathioprine",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy",
"       </td>",
"       <td>",
"        <p>",
"         Lymphoma",
"        </p>",
"        <p>",
"         Leukemia",
"        </p>",
"        <p>",
"         Metatstatic carcinomas and adenocarcinomas",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Sarcoid",
"        </p>",
"        <p>",
"         Behcet's disease",
"        </p>",
"        <p>",
"         Systemic lupus erythematosus",
"        </p>",
"       </td>",
"       <td>",
"        Vogt-Koyanagi-Harada syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Epidermoid cyst",
"        </p>",
"        <p>",
"         Postvaccination",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Etiologies are classified according to their relative frequency among all causes of aseptic meningitis.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Connolly, KJ, Hammer, SM. Infect Dis Clin North Am 1990; 4:599.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_30_18925=[""].join("\n");
var outline_f18_30_18925=null;
var title_f18_30_18926="Local control and survival pulmonary metastectomy";
var content_f18_30_18926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effect of local control on survival following repeat metastasectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 342px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Preservation of local control in the chest is associated with long term survival following repeat metastasectomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_30_18926=[""].join("\n");
var outline_f18_30_18926=null;
var title_f18_30_18927="Ambulatory ePAD during progression of diastolic heart failure";
var content_f18_30_18927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Ambulatory ePAD during progression of diastolic heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 398px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Changes in LV diastolic pressure as reflected by ambulatory 24-hour median pulmonary artery diastolic pressures (ePAD) in a patient with diastolic heart failure (HF). Time zero represents the day of hospitalization for acute decompensated HF and Day -60 marks 60 days prior to the onset of this event. As shown, left ventricular diastolic pressure is elevated even with compensated HF-PEF and then rises as diastolic HF worsens. Following treatment the diastolic pressure falls to a level close to that in the preceding compensated phase.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Based on data from: Zile MR, Bennett TD, St John Sutton M, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 2008; 118:1433. Courtesy of Dr. Michael Zile.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_30_18927=[""].join("\n");
var outline_f18_30_18927=null;
